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Introduction {#tjp13730-sec-0030}
============

Patient variability is one of the most daunting aspects of forecasting arrhythmia vulnerability in response to inherited disease or drug application. Considerable differences in drug impacts are routinely observed from patient to patient, with significant overlap between normal and pathological variants (Leopold & Loscalzo, [2018](#tjp13730-bib-0044){ref-type="ref"}). However, genotype, and even sex, have not been sufficiently considered as a biological variable when developing pharmacotherapy regimes (Schwartz *et al*. [1995](#tjp13730-bib-0080){ref-type="ref"}; Schwartz *et al*. [2001](#tjp13730-bib-0081){ref-type="ref"}; Shah & Carter, [2008](#tjp13730-bib-0082){ref-type="ref"}; Jamshidi *et al*. [2012](#tjp13730-bib-0032){ref-type="ref"}; Kaab *et al*. [2012](#tjp13730-bib-0034){ref-type="ref"}; Behr & Roden, [2013](#tjp13730-bib-0003){ref-type="ref"}). There is a profound need to develop a strategy to predict the diverse mechanisms of arrhythmia vulnerability across patient populations.

A promising emerging experimental method utilizes induced pluripotent stem cell‐derived cardiomyocytes (iPSC‐CMs). iPSC‐CMs are an increasingly utilized patient‐specific cardiac cell model because they recapitulate cellular electrical properties of normal and diseased phenotypes, preserve patient‐specific genotype and demonstrate expected pharmacological responses of adult cardiomyocytes (Moretti *et al*. [2010](#tjp13730-bib-0058){ref-type="ref"}; Itzhaki *et al*. [2011](#tjp13730-bib-0030){ref-type="ref"}; Terrenoire *et al*. [2013](#tjp13730-bib-0089){ref-type="ref"}; Sallam *et al*. [2015](#tjp13730-bib-0076){ref-type="ref"}). iPSC‐CMs derive from adult somatic cells reprogrammed to the embryonic‐like state and then differentiated to cardiomyocytes (Takahashi & Yamanaka, [2006](#tjp13730-bib-0087){ref-type="ref"}). Cell‐based models for multiple cardiac diseases have been developed using iPSC‐CMs and show the preservation of patient‐specific disease markers carried from the source patient to the patient‐derived iPSC‐CMs (Moretti *et al*. [2010](#tjp13730-bib-0058){ref-type="ref"}; Itzhaki *et al*. [2011](#tjp13730-bib-0030){ref-type="ref"}; Lan *et al*. [2013](#tjp13730-bib-0042){ref-type="ref"}; Garg *et al*. [2018](#tjp13730-bib-0020){ref-type="ref"}). The retention of patient‐specific disease markers makes iPSC‐CMs an ideal tool for investigating the patient‐specific disease and response. Indeed, iPSC‐CMs are currently being utilized in preclinical drug testing and prediction of genotype--phenotype relationships (Sun *et al*. [2012](#tjp13730-bib-0086){ref-type="ref"}; Lan *et al*. [2013](#tjp13730-bib-0042){ref-type="ref"}; Liang *et al*. [2013](#tjp13730-bib-0046){ref-type="ref"}; Navarrete *et al*. [2013](#tjp13730-bib-0062){ref-type="ref"}; Burridge *et al*. [2016](#tjp13730-bib-0008){ref-type="ref"}).

One of the limitations of iPSC‐CMs as a model of adult cardiac behaviour is their immature phenotype, which more closely resembles fetal cardiomyocytes. The immature iPSC‐CM phenotype is characterized by spontaneous beating, significant differences in potassium currents compared to adult cardiac cells and the presence of early‐developmental currents (Bett *et al*. [2013](#tjp13730-bib-0006){ref-type="ref"}; Karakikes *et al*. [2014](#tjp13730-bib-0037){ref-type="ref"}). Additionally, iPSC‐CMs have immature calcium handling as a result of their lack of T‐tubules and differences in sarcoplasmic reticulum (SR) calcium handling (Yang *et al*. [2014](#tjp13730-bib-0101){ref-type="ref"}). Recent experimental developments have enhanced the maturation of iPSC‐CMs by mimicking the natural environment, which allows for staged transitions of cardiomyocytes from the embryonic to adult phenotype (Kamakura *et al*. [2013](#tjp13730-bib-0035){ref-type="ref"}; Nunes *et al*. [2013](#tjp13730-bib-0064){ref-type="ref"}; Herron *et al*. [2016](#tjp13730-bib-0026){ref-type="ref"}; Tiburcy *et al*. [2017](#tjp13730-bib-0090){ref-type="ref"}).

Another persistent concern with iPSC‐CM technology has been the vast diversity of phenotypes observed *in vitro*. One reason for the variability between iPSC‐CMs undoubtedly arises from the differences in genetic information of donors (DeBoever *et al*. [2017](#tjp13730-bib-0013){ref-type="ref"}). Variation as a result of genetic differences is a critical attribute of iPSC‐CMs because it allows for the observation of a variety of naturally occurring phenotypes and reflects patient‐specific vulnerability to rare events, such as arrhythmia. However, even iPSC‐CMs derived from the same donor with identical genetic information may display persistently variable phenotypes as a result of unknown sources of variation. There are a number of potential sources of variability, not least of all the complex process of generating and culturing iPSC‐CMs and the influence of precise maturation phases (Narsinh *et al*. [2011](#tjp13730-bib-0061){ref-type="ref"}). Action potential (AP) morphologies and calcium transients (CaTs) have been shown to vary both within independent laboratories (Doss *et al*. [2012](#tjp13730-bib-0016){ref-type="ref"}; Du *et al*. [2015](#tjp13730-bib-0017){ref-type="ref"}) and across laboratories (Hwang *et al*. [2015](#tjp13730-bib-0029){ref-type="ref"}).

Although the iPSC‐CMs that are utilized *in vitro* allow for observation of a variety of responses to drugs and other perturbations, a major drawback in the experimental setting is the lack of a high throughput method to link underlying genomic, proteomic, or ionic mechanisms to the observed whole‐cell behaviours. Population‐based computational modelling provides a powerful tool in closing this gap via *in silico* analysis of variability in cardiac electrophysiology (Muszkiewicz *et al*. [2016](#tjp13730-bib-0060){ref-type="ref"}; Yang *et al*. [2016](#tjp13730-bib-0099){ref-type="ref"}; Passini *et al*. [2017](#tjp13730-bib-0072){ref-type="ref"}; Ni *et al*. [2018](#tjp13730-bib-0063){ref-type="ref"}). Implementation of these approaches in the modelling and simulation of iPSC‐CMs has the potential to reconcile multiple datasets, define physiological ranges of variability and identify vulnerable parameter regimes (Sarkar & Sobie, [2010](#tjp13730-bib-0077){ref-type="ref"}; Yang & Clancy, [2012](#tjp13730-bib-0098){ref-type="ref"}; Britton *et al*. [2013](#tjp13730-bib-0007){ref-type="ref"}; Yang *et al*. [2015](#tjp13730-bib-0100){ref-type="ref"}; Morotti & Grandi, [2017](#tjp13730-bib-0059){ref-type="ref"}). With respect to using iPSC‐CMs for cardiotoxicity testing of pharmacological interventions, the US Food and Drug Administration has outlined the Comprehensive In Vitro Proarrhythmia Assay (CiPA) protocol for combining cellular iPSC‐CM outputs with computational approaches (Fermini *et al*. [2016](#tjp13730-bib-0019){ref-type="ref"}). These efforts will be further strengthened by a high throughput computational approach to study the mechanisms underlying phenotypic variability in iPSC‐CMs.

Although prior studies have addressed computational modelling of iPSC‐CMs (Paci *et al*. [2013](#tjp13730-bib-0068){ref-type="ref"}; Koivumaki *et al*. [2018](#tjp13730-bib-0040){ref-type="ref"}), there is a need for a computational model which incorporates the wide‐range of experimental measurements from iPSC‐CMs. Paci *et al*. ([2013](#tjp13730-bib-0068){ref-type="ref"}) have developed a computational model of the iPSC‐CM that is based on a single iPSC‐CM experimental electrophysiology study. As a result of the lack of experimental data available at the time, the model is largely based on *I*--*V* curves measured in iPSC‐CMs by Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}). Model kinetics were largely retained from the adult ventricular model of ten Tusscher *et al*. ([2004](#tjp13730-bib-0088){ref-type="ref"}), with any additional changes based on experimental data from animal or adult human cells (ten Tusscher *et al*. [2004](#tjp13730-bib-0088){ref-type="ref"}; Paci *et al*. [2012](#tjp13730-bib-0071){ref-type="ref"}). Although this model captures the spontaneously beating iPSC‐CM AP phenotype, it is based on a limited description of iPSC‐CM behaviour. Later iterations of iPSC‐CM models by Paci *et al*. ([2018](#tjp13730-bib-0067){ref-type="ref"}) and Koivumaki *et al*. ([2018](#tjp13730-bib-0040){ref-type="ref"}) incorporated modifications to improve calcium handling; however, these adaptations were made with limited experimental data to define the range of calcium transient behaviour during the AP. The model presented in this study is constrained by several calcium handling datasets that have not been utilized in parameterizing prior models, including concentration measurements of the iPSC‐CM calcium transient during the AP.

Other computational studies have adapted the framework of Paci *et al*. ([2018](#tjp13730-bib-0067){ref-type="ref"}) to model specific phenotypes and populations of iPSC‐CMs (Lei *et al*. [2017](#tjp13730-bib-0043){ref-type="ref"}; Paci *et al*. [2017](#tjp13730-bib-0070){ref-type="ref"}; Koivumaki *et al*. [2018](#tjp13730-bib-0040){ref-type="ref"}; Paci *et al*. [2018](#tjp13730-bib-0067){ref-type="ref"}; Tveito *et al*. [2018](#tjp13730-bib-0091){ref-type="ref"}); however, none of these efforts have utilized *in vitro* kinetics data to implement experimentally informed variation of iPSC‐CMs. There is a wide range iPSC‐CM phenotypes that are not captured by previous approaches to modelling iPSC‐CMs. Because there is a wide range of 'normal' iPSC‐CM behaviours characterized by distinct experimental laboratories, we present a comprehensive computational model that captures this experimental variability.

The goal of the present study is to extend the iPSC‐CM technology by developing an *in silico* complement: a high throughput method for analysing phenotypic mechanisms of emergent behaviours in normal control iPSC‐CMs. This is achieved by computationally modelling phenotypic variability in control iPSC‐CMs via simple models based on source data from multiple laboratories. The use of simplified models to describe ionic gating kinetics allows us to fully parameterize a model to fit multiple individual experimental datasets. This approach allowed for the rapid construction of model populations from multiple data sets, at the same time as setting the stage for future expansion into patient specific electrophysiology models by allowing reparameterization from data collected from donor cells.

Additionally, this allows us to investigate whether kinetic variability can explain whole‐cell variation observed in iPSC‐CMs experimentally. Here, we show that predicted experimental variability at the subcellular level can recapitulate the full range of *in vitro* whole‐cell iPSC‐CM behaviour in an *in silico* cellular population. The population can further be used to identify subpopulations of interest, including immature and mature phenotypes, and clarify the underlying processes that characterize the phenotypes. In the future, our approach can also be used to examine mechanism of disease and drug effects. The computational models of iPSC‐CMs will allow for identification of parameter regimes with increased proclivity to arrhythmia in the presence of genetic mutation or pharmacological intervention. The tools may be applied for *in silico* screening and prediction of drug effects on varied genetic backgrounds to predict patient pharmacological responses.

Methods {#tjp13730-sec-0040}
=======

All source code and instructions are freely available on the GitHub (<https://github.com/ClancyLabUCD/IPSC-model>).

Model construction {#tjp13730-sec-0050}
------------------

As in prior cardiomyocytes models (Rudy & Silva, [2006](#tjp13730-bib-0075){ref-type="ref"}), the iPSC‐CM can be described by the differential equation: $$\frac{dV}{dt} = \frac{- I_{ion} + I_{stim}}{C_{m}}$$where *V* is voltage, *t* is time, *C* ~m~ is membrane capacitance, *I* ~ion~ is the sum of transmembrane currents and *I* ~stim~ is the stimulus current (*I* ~stim~ = 0 pA/pF in spontaneously beating cells). The iPSC‐CM model (schematic representation in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}, left) includes 13 transmembrane currents, such that: $$\begin{array}{ccl}
I_{ion} & = & {I_{Na} + I_{CaL} + I_{Kr} + I_{Ks} + I_{K1} + I_{to} + I_{f} + I_{CaT}} \\
 & & {+ \, I_{NCX} + I_{PMCA} + I_{NaK} + I_{bCa} + I_{bNa}} \\
\end{array}$$A schematic of the model cell containing all the ionic processes and compartments in the model is shown in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}. Seven key transmembrane currents (*I* ~Na~, *I* ~CaL~, *I* ~Kr~, *I* ~Ks~, *I* ~K1~, *I* ~to~ and *I* ~f~, indicated by red stars in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}), were reformulated using Hodgkin--Huxley‐type gating formulations (Hodgkin & Huxley, [1952](#tjp13730-bib-0027){ref-type="ref"}). For each of these currents, single exponential rate‐constants (Fig. [1](#tjp13730-fig-0001){ref-type="fig"}, right) were optimized to iPSC‐CM experimental data (Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, step 1a). The remaining currents shown in Fig. [1](#tjp13730-fig-0001){ref-type="fig"} were modelled using formulations from previously published cardiac models (Shannon *et al*. [2004](#tjp13730-bib-0083){ref-type="ref"}; ten Tusscher *et al*. [2004](#tjp13730-bib-0088){ref-type="ref"}; Maltsev & Lakatta, [2009](#tjp13730-bib-0052){ref-type="ref"}), and tuned to recapitulate experimental data for whole‐cell outputs of iPSC‐CMs. Details describing the experimental data used and resulting model formulations are provided in the Results.

![A schematic of the computational iPSC‐CM model\
Red stars indicate individual currents (\**I* ~Na~, *I* ~CaL~, *I* ~Kr~, *I* ~Ks~, *I* ~K1~, *I* ~to~ and *I* ~f~), formulated using single‐exponential voltage‐dependent rate constants. Parameters were optimized to experimental iPSC‐CM kinetic data. The mathematical formulation for an example current, *I* ~Na~, is shown on the right. All gating variables in the starred currents were modelled using the example formula for gating variable *x*. Additional calcium‐dependent currents (*I* ~NCX~, *I* ~PMCA~, *I* ~CaT~ and SR currents: *I* ~SERCA~, *I* ~RyR~ and *I* ~leak~) were modelled using previously published model formulations, optimized to calcium transient data from iPSC‐CMs. Remaining currents (*I* ~NaK~, *I* ~bCa~, *I* ~bNa~) were modelled using ten Tusscher 2004 formulations optimized to recapitulate iPSC‐CM AP data.](TJP-597-4533-g002){#tjp13730-fig-0001}

![Flow chart\
Flow chart showing the methodology for building the iPSC‐CM model populations.](TJP-597-4533-g003){#tjp13730-fig-0002}

The iPSC‐CM ion dynamics were formulated as performed previously (DiFrancesco & Noble, [1985](#tjp13730-bib-0015){ref-type="ref"}; Luo & Rudy, [1994](#tjp13730-bib-0049){ref-type="ref"}; ten Tusscher *et al*. [2004](#tjp13730-bib-0088){ref-type="ref"}), assuming rapid equilibrium approximation for calcium buffers in various compartments: $$\begin{array}{ccl}
\frac{dCa_{i}}{dt} & = & {Ca_{{Buf},c}} \\
 & & {\times \,\left\lbrack {- \frac{I_{CaL,Ca} + I_{CaT} + I_{PMCA} + I_{bCa} - 2I_{NCX}}{2V_{c}F}} \right.} \\
 & & \left. {+ \, J_{Rel} - J_{up} + J_{leak}} \right\rbrack \\
\end{array}$$ $$\frac{dCa_{SR}}{dt} = Ca_{{Buf},{SR}} \ast \frac{V_{c}}{V_{SR}}{({- J_{Rel} + J_{Up} - J_{leak}})}$$ $$\begin{array}{rcl}
{Ca_{{Buf},X}} & = & {\frac{1}{1 + \frac{Buf_{x} \ast K_{{Buf},X}}{{({\lbrack Ca\rbrack}_{X} + K_{{Buf},X})}^{2}}},} \\
{{for}\; X} & = & {{cytoplasm}\;(C),\;\text{sarcoplasmic}\text{reticulum}\;({SR})} \\
\end{array}$$ $$\begin{array}{r}
{\frac{dNa_{i}}{dt} = - \frac{I_{Na} + I_{f,{Na}} + I_{{CaL},{Na}} + I_{bNa} + 3I_{NCX} + 3I_{NaK}}{V_{c}F}} \\
\end{array}$$ $$\begin{array}{ccl}
 & & {\frac{dK_{i}}{dt} =} \\
 & & {\quad - \frac{I_{Kr} + I_{Ks} + I_{K1} + I_{to} + I_{f,K} + I_{{CaL},K} - 2I_{NaK} + I_{stim}}{V_{c}F}} \\
\end{array}$$where *F* is the Faraday constant, *V* ~C~ is the cytoplasmic volume, *V* ~SR~ is the sarcoplasmic reticulum volume, *Buf* ~X~ is the total buffer concentration in a given compartment and *K* ~Buf,X~ is the half‐saturation constant of the buffer in a given compartment. Total volume and cytoplasmic buffering constants in the iPSC‐CM model were set to experimental measurements in iPSC‐CMs from (*V* ~total~ = *V* ~C~ + *V* ~SR~ = 3960 µm^3^, *Buf* ~C~ = 0.06 m[m]{.smallcaps} and *K* ~Buf,C~ = 0.0006 m[m]{.smallcaps}) (Hwang *et al*. [2015](#tjp13730-bib-0029){ref-type="ref"}). Remaining SR buffering parameters (*Buf* ~SR~, *K* ~Buf,SR~) were optimized in the whole‐cell optimization (Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, Step 2). Relative proportions of volumes (*V* ~C~:*V* ~SR~), were retained from the adult human ventricular model by ten Tusscher *et al*. ([2004](#tjp13730-bib-0088){ref-type="ref"}), referred to as the ten Tusscher 2004 model. Capacitance of the cell was set to 60 pF, based on the experimentally observed range in iPSC‐CMs (18--89 pF) (Ma *et al*. [2011](#tjp13730-bib-0051){ref-type="ref"}; Hwang *et al*. [2015](#tjp13730-bib-0029){ref-type="ref"}; Li *et al*. [2017](#tjp13730-bib-0045){ref-type="ref"}).

The models were implemented in MATLAB, version R2017a (MathWorks Inc., Natick, MA, USA) and solved using ode15s.

AP morphology {#tjp13730-sec-0060}
-------------

APs in the baseline model and populations were evaluated by computing a series of AP morphology markers. Maximum diastolic potential (MDP) was the most negative voltage during the AP. Maximal upstroke velocity (dV/dt~max~) was the maximal slope between two points in the computed AP upstroke. AP amplitude (Amp) was calculated as the difference in voltage between MDP and the peak voltage during the AP. AP duration (APD~x~) was the time between dV/dt~max~ and *X*% AP repolarization from the peak voltage (e.g. For APD~90~, time from dV/dt~max~ to *V* ~m~ = Peak − 0.9\*Amp).

Parameter optimization of reformulated ionic channel models (Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, step 1b) {#tjp13730-sec-0070}
-------------------------------------------------------------------------------------------------------------------

For each of the reformulated currents, model parameters were optimized to multiple experimental datasets, resulting in dataset‐specific parameterization instances of the model. For each dataset‐specific model, external ion concentrations and voltage protocols were set to reflect the corresponding experimental conditions. Experimental conditions for each dataset are described in Table [1](#tjp13730-tbl-0001){ref-type="table"}. All of the experimental data used to optimize the models were collected in iCell iPSC‐CMs at physiological temperature (37°C), unless otherwise specified (in which cases, data were temperature‐corrected with appropriate *Q* ~10~ values, as specified in the Results for the corresponding ionic current). This process was used to generate dataset‐specific models. As an example, consider three separate experimental iPSC‐CM datasets for a given current: datasets A, B and C. In the case of the sodium current (Fig. [3](#tjp13730-fig-0003){ref-type="fig"}), this would refer to (A) Ma *et al*. (B) Jalife Immature, (C) Jalife Mature.

###### 

Experimental conditions for all datasets used in optimization of ionic current models

                                                                                                       Extracellular (m[m]{.smallcaps})   Intracellular (m[m]{.smallcaps})                                          
  ------ --------------------------------------------------------------- -------- -------- ----------- ---------------------------------- ---------------------------------- ----- ----- ----- ----- ----- ---- --- ---
  INa    Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"})         35--37     5        iCell    50                                                                    1.8                           10   2   
         Herron *et al*. (2016) (PDMS/glass)                              21--22   19/12      iCell    20                                                                    1.8                           5        
         Kurokawa Lab (Li *et al*., 2017)                                   25       5        iCell    30                                                                    2                                      5
  ICaL   Es‐Salah‐Lamoureux *et al*. (2016)                                room    15--17      IHC                                                                           5                             5    2   
         Veerman *et al*. (2016)                                            36       21        IHC                                                                           1.8                                    
         Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"})          room      5        iCell                                                                          5                             5    2   
  ICaT   Kurokawa Lab (Li *et al*., 2017)                                   36       2        iCell                                                                          5                                      5
  IKr    Bellin *et al*. (2013)                                             37       14        IHC     140                                5.4                                1.8         20    125                  
         Es‐Salah‐Lamoureux *et al*. (2016)                                 35       21        IHC     140                                4                                  1           20    125                  
         Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"})         35--37     8        iCell    150                                5.4                                1.8         150               5    2   
         Wu Lab (Garg *et al*. 2018)                                      36--37     4         IHC     150                                5.4                                1.8         120                        
  Ito    Veerman *et al*. (2016)                                            36       13        IHC     140                                5.4                                1.8         20    105         5        
         Cordeiro *et al*. (2013)                                           36       14       iCell    126                                5.4                                2           10          125   10   5   
         Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"})         35--37     8        iCell                                       5.4                                      160         150              5   
  IKs    Ma, Wei *et al*. ([2015](#tjp13730-bib-0050){ref-type="ref"})      37      7/8     IHC/iCell  140                                5.4                                1.7         50          80             
         Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"})         35--37     5        iCell    150                                5.4                                1.8         20          125            
  If     Kurokawa Lab (Li *et al*. 2017)                                    36       9        iCell    135                                5.4                                1.8         30                     1   
         Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"})         35--37     17       iCell    135                                5.4                                1.8         150               5    2   
  IK1    Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"})         35--37     4        iCell                                       5.4                                      160         150                  
         Herron *et al*. (2016) (PDMS/glass)                              21--22    5/7       iCell    148                                5.4                                1.8         148                        
         Kurokawa Lab (Li *et al*. 2017)                                    36       7        iCell    135                                5.4                                1.8         20                     1   

^\*^IHC, in‐house control cell‐line.
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![Sodium current (*I* ~Na~) model optimization\
*A*, steady‐state inactivation and activation curves. Dataset‐specific model fits (lines) optimized to experimental data (points). The sodium current model used in the baseline whole‐cell model is shown in black. Colours represent distinct experimental iPSC‐CM data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) and from immature and mature cell preparations from the Jalife lab (Herron *et al*. [2016](#tjp13730-bib-0026){ref-type="ref"}). *B*, *I*--*V* curves for *I* ~Na~. Dataset‐specific models were simulated using the experimental conditions of the corresponding experimental data. *C*, *I* ~Na~ activation (*m*‐gate) time constants. *D*, *I* ~Na~ fast‐inactivation (*h*‐gate) time constants. *E*, I~Na~ slow‐inactivation (*j*‐gate) time constants. *j*‐gate time constant parameters for all *I* ~Na~ models were optimized to experimental iPSC‐CM data from the Kurokawa lab (Li *et al*. [2017](#tjp13730-bib-0045){ref-type="ref"}).](TJP-597-4533-g004){#tjp13730-fig-0003}

Considering gating variable *x* in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}, parameters *x* ~1--5~ were optimized to recapitulate the experimental kinetics for gate *x*. In Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, this is shown as Step 1b in the upper highlighted box indicating the optimization routine. Parameter optimization minimized the error between the model and experimental voltage‐dependence of the steady‐state and time constants of a given gate. The error function was the sum of the log squared difference between the data and model fit, normalized to the size of the dataset. The 'fminsearch' function was used in MATLAB to implement Nelder--Mead minimization of the error function. Random small perturbations (\<10%) were applied to resulting local minima, to improve data fit. The parameter fit with the minimal error function value after 100 perturbations was used as the optimal model fit to the data. This is a relatively simple approach which only requires standard MATLAB functions, allowing for additional dataset‐specific models to be easily obtained and incorporated into the model in the future. Additionally, this approach has been previously utilized for optimization of more complex ionic current models and datasets (Moreno *et al*. [2016](#tjp13730-bib-0056){ref-type="ref"}). The ionic current models in the present study were chosen to minimize the number of optimized parameters, thus this approach was sufficient to successfully fit the models to the datasets presented.

These simplified models also allow for a more physiological understanding of model parameterizations. The ionic current model parameters can be combined such that: $$\begin{array}{r}
{x_{\infty} = \frac{\alpha_{x}}{\alpha_{x} + \beta_{x}} = \frac{1}{1 + \frac{\beta_{x}}{\alpha_{x}}} = \frac{1}{1 + \frac{x_{3}e^{V/x_{4}}}{x_{1}e^{V/x_{2}}}} = \frac{1}{1 + x_{6}e^{\frac{V}{x_{7}}}}} \\
\end{array}$$where: $$x_{6} = \frac{x_{3}}{x_{1}},\quad x_{7} = \frac{1}{\left( {\frac{1}{x_{4}} - \frac{1}{x_{2}}} \right)}$$

With this simplification, we can understand the parameter effect on the voltage dependence of steady‐state behaviour. The x~∞~ function has a sigmoidal voltage‐dependence which is characterized by the slope and *V* ~half~, where *x* ~∞~(*V* ~half~) = 0.5. Using the parameter combinations shown in eqn [(8)](#tjp13730-disp-0008){ref-type="disp-formula"}, *x* ~6~ and *x* ~7~ are proportional to *V* ~half~ and slope, respectively.

Constructing the average parameter set for reformulated currents (Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, step 1c) {#tjp13730-sec-0080}
------------------------------------------------------------------------------------------------------------------------

Consider parameter *x* ~1~ in any gating variable. The value of *x* ~1~ is determined via parameter optimization to an experimental dataset. If three experimental datasets (datasets A, B and C) are used, then each dataset corresponds to a unique parameter value of *x* ~1~ (*x* ~1A~, *x* ~1B~, *x* ~1C~) in each dataset‐specific model. The baseline model is composed of average parameters values for *x* ~1~, such that: $$x_{1,{avg}} = \frac{x_{1A} + x_{1B} + x_{1C}}{3}$$This is repeated for each parameter in the ionic current model. These averaged parameters (*x* ~1--5,avg~, *g* ~x,avg~) comprise an average model for each current. The baseline model for each current was constructed using the average model gating kinetics. The baseline model is the starting point to implement variability.

Constructing the parameter distributions for reformulated currents (Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, step 1d) {#tjp13730-sec-0090}
--------------------------------------------------------------------------------------------------------------------------

To create a population of models that capture variability between the dataset‐specific models, we created a distribution for each parameter in the reformulated currents. This distribution is centred at the baseline ionic current model value. Similar to our approach in selecting an optimization method (Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, step 1b), the sampling method was chosen for simplicity and to allow for variation in a large number of parameters. Although the range of variability was determined by the range of the experimental datasets used to in form the model, there is still insufficient data to accurately determine to distribution of data between these datasets (constructing the distribution of experimental data would require more data than the two to five datasets per ionic current used in this study). For simplicity we used a normal distribution of parameters, and randomly selected the parameter values in building the population of models.

For example, for each cell in the population of models, the value of *x* ~1~ is randomly chosen from a normal distribution around *x* ~1,avg~. The normal distribution is created using *x* ~1,avg~ and the SD of *x* ~1A~, *x* ~1B~ and *x* ~1C~, as described above. This same process is used to create a distribution for each parameter (*x* ~1--5~) in each model gating variable, and for the maximal conductance (*g* ~x~).

Optimization of the baseline whole‐cell model (Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, step 2) {#tjp13730-sec-0100}
----------------------------------------------------------------------------------------------------

The pre‐optimized whole cell model is composed of average parameter sets for the reformulated currents combined with non‐reformulated currents from existing models in the whole‐cell model structure and geometry as described above. To tune parameters in non‐reformulated currents, as well as calcium handling parameters that were not directly defined by experiments, we implemented an optimization of the whole‐cell model. This is shown in Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, step 2, the second highlighted optimization routine in the flowchart.

To optimize the whole‐cell model, 'fminsearchbnd' function was used in MATLAB to implement Nelder--Mead minimization of the error function. This 'bound' version of the Nelder--Mead algorithm was used to maintain the reformulated maximal conductances within a ±20% range of *g* ~x,avg~ from the pre‐optimized baseline model. The maximal conductance of the reformulated currents, maximal conductances and fluxes of the remaining currents, SR buffering constants, calcium‐dependent inactivation in *I* ~CaL~, RYR rate constants and NCX kinetic parameters were optimized to fit whole‐cell behaviour within the experimentally observed range for iPSC‐CMs. As in the optimization of the ionic currents, the error function was defined as the sum of the log squared difference between the experimental data and whole‐cell model output. The targets for the optimization function considered the experimentally observed range of AP morphology (MDP, APD~90~, AP amplitude, maximal upstroke velocity), CaT morphology (time constant of decay, time to peak, ratio of time constant of decay and time to peak, CaT amplitude and diastolic \[Ca^2+^\]), calcium handling response to caffeine (peak calcium and decay, not shown) (Hwang *et al*. [2015](#tjp13730-bib-0029){ref-type="ref"}) and contribution of SERCA, NCX and PMCA to calcium efflux from the cytosol.

The ionic current models shown as black lines in Figs 3--9 are the final version of each current model, including all tuning of maximal conductance in the whole‐cell optimization. The baseline model resulting from this optimization was used as the starting point for all subsequent populations. All parameters which were not randomized in the model populations (remaining currents, cell geometry, etc.) were kept at the baseline model values.

![Calcium current model optimization\
*A*, L‐type calcium current (*I* ~CaL~) steady‐state inactivation and activation curves with dataset‐specific model fits (lines) optimized to experimental data (points). The L‐type calcium model used in the baseline cellular model is shown in black. Coloured symbols represent experimental iPSC‐CM data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}), Veerman *et al*. ([2016](#tjp13730-bib-0095){ref-type="ref"}) and Es‐Salah‐Lamoureux *et al*. ([2016](#tjp13730-bib-0018){ref-type="ref"}). *B*, *I*--*V* curves for *I* ~CaL~. Calcium‐dependent gating model formulation retained from ten Tusscher 2004 adult cardiomyocyte model with parameter optimization to fit whole cell iPSC‐CM outputs. *C*, time constants of *I* ~CaL~ activation gate. Time constant parameters for all *I* ~CaL~ models were optimized to experimental iPSC‐CM data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}). *D*, time constants of *I* ~CaL~ inactivation gate. *E*, optimization of peak T‐type calcium current (*I* ~CaT~) to experimental iPSC‐CM data from the Kurokawa lab (Li *et al*. [2017](#tjp13730-bib-0045){ref-type="ref"}). Model formulation of *I* ~CaT~ was retained from the Maltsev and Lakatta sinoatrial node model.](TJP-597-4533-g005){#tjp13730-fig-0004}

![Rapid delayed rectifier potassium current (*I* ~Kr~) model optimization\
*A*, steady‐state activation with dataset‐specific model fits (lines) optimized to experimental data (points). The *I* ~Kr~ model used in the baseline cellular model is shown in black. Coloured symbols represent experimental iPSC‐CM data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}), the Wu lab (Garg *et al*. [2018](#tjp13730-bib-0020){ref-type="ref"}), Es‐Salah‐Lamoureux *et al*. ([2016](#tjp13730-bib-0018){ref-type="ref"}) and Bellin *et al*. ([2013](#tjp13730-bib-0004){ref-type="ref"}). For *I* ~Kr~ inactivation gating, existing ten Tusscher 2004 model components were reformulated to single exponential forms. *B*, *I*--*V* curves for *I* ~Kr~.*C*, time constants of the *I* ~Kr~ activation gate. Activation time constants for the models of Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}), the Wu lab (Garg *et al*. [2018](#tjp13730-bib-0020){ref-type="ref"}) and Es‐Salah‐Lamoureux *et al*. ([2016](#tjp13730-bib-0018){ref-type="ref"}) were optimized to experimental iPSC‐CM data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}). *D*, time constants of *I* ~Kr~ inactivation gate using the ten Tusscher 2004 model reformulated to single exponential forms.](TJP-597-4533-g006){#tjp13730-fig-0005}

![Transient outward potassium current (*I* ~to~) model optimization\
*A*, steady‐state activation and inactivation curves with dataset‐specific model fits (lines) optimized to experimental data (points). The *I* ~to~ model used in the baseline cellular model is shown in black. Coloured symbols represent experimental iPSC‐CM data from Veerman *et al*. ([2016](#tjp13730-bib-0095){ref-type="ref"}), Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) and Cordeiro *et al*. ([2013](#tjp13730-bib-0011){ref-type="ref"}). *B*, *I*--*V* curves for *I* ~to~. *C*, time constants of *I* ~to~ activation gate. For activation time constants in all I~to~ models, the ten Tusscher 2004 I~to~ activation time constants were reformulated to single exponential forms. *D*, time constants of I~to~ inactivation gate. Model time constant parameters of Veerman *et al*. ([2016](#tjp13730-bib-0095){ref-type="ref"}) were optimized to iPSC‐CM experimental data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}).](TJP-597-4533-g007){#tjp13730-fig-0006}

![Slow delayed rectifier potassium current (*I* ~Ks~) model optimization\
*A*, steady‐state activation with dataset‐specific model fits (lines) optimized to experimental data (points). The *I* ~Ks~ model used in the baseline cellular model is shown in black. Coloured symbols represent experimental iPSC‐CM data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) and two separate iPSC‐CM cell‐line datasets in Ma *et al*. ([2015](#tjp13730-bib-0050){ref-type="ref"}). *B*, time constants of the *I* ~Ks~ activation gate. Time constants for all I~Ks~ models were optimized to experimental iPSC‐CM data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}). *C*, *I*--*V* curves for *I* ~Ks~.](TJP-597-4533-g008){#tjp13730-fig-0007}

![Pacemaker/funny current (*I* ~f~) model optimization\
*A*, steady‐state activation with dataset‐specific model fits (lines) optimized to experimental data (points). The *I* ~f~ model used in the baseline cellular model is shown in black. Coloured symbols represent experimental iPSC‐CM data from the Kurokawa lab (Li *et al*. [2017](#tjp13730-bib-0045){ref-type="ref"}) and Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}). *B*, time constants of the *I* ~f~ inactivation gate. *C*, *I*--*V* curves for *I* ~f~.](TJP-597-4533-g009){#tjp13730-fig-0008}

![Inward rectifier potassium current (*I* ~K1~) model optimization\
*I*--*V* curves for *I* ~K1~ with dataset‐specific model fits (lines) optimized to experimental data (points). The *I* ~K1 ~model used in baseline cellular model is shown in black. Coloured symbols represent experimental iPSC‐CM data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}), the Kurokawa lab (Li *et al*. [2017](#tjp13730-bib-0045){ref-type="ref"}) and immature and mature cell preparations from the Jalife lab (Herron *et al*. [2016](#tjp13730-bib-0026){ref-type="ref"}).](TJP-597-4533-g010){#tjp13730-fig-0009}

Sensitivity analysis {#tjp13730-sec-0110}
--------------------

To further analyse the baseline models (Figs [11](#tjp13730-fig-0011){ref-type="fig"} *E* and [15](#tjp13730-fig-0015){ref-type="fig"} *C*), parameter sensitivity was conducted using multivariable linear regression (Sobie, [2009](#tjp13730-bib-0085){ref-type="ref"}). Sensitivity analysis was conducted based on variation of the maximal conductance and maximal ion transport rates of the transmembrane currents (*I* ~Na~, *I* ~CaL~, *I* ~CaT,~ *I* ~Kr~, *I* ~Ks~, *I* ~K1~, *I* ~to~, *I* ~f~, *I* ~NCX~, *I* ~NaK~, *I* ~PMCA~, *I* ~bNa~ and *I* ~bCa~) and SR fluxes (*J* ~Up~, *J* ~Rel~ and *J* ~leak~). The remaining parameters, including all parameters describing model kinetics, were held at the baseline model values. Random scaling factors were chosen from a log‐normal distribution with a median value of 1, SD of 0.1. In total, 5000 randomly parameterized models were run for each sensitivity analysis shown. For the baseline population (Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *E*; immature in Fig. [15](#tjp13730-fig-0015){ref-type="fig"} *C*) only spontaneously beating, AP generating, models were analysed. This resulted in 89.3% model retention rate. For the mature population, only stimulated beating, AP generating, models were analysed. This resulted in 67.2% model retention rate. For each analysis shown, 50 randomly determined subpopulations of 1000 models were analysed, resulting in a SD of less than 0.025 for all regression bars shown. Each cell simulation was run until there was a \<1% change in minimum ion concentration (for Ca~i~, Ca~SR~, Na~i~ and K~i~) between the first and last beat during a 50 s simulation run. Once the steady‐state criteria were met (ranging from 60 to 600 s), the final AP was saved for regression analysis.

Development of population‐based models based on experimental variability (Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, step 3) {#tjp13730-sec-0120}
-------------------------------------------------------------------------------------------------------------------------------

To create a population of models (as shown in Figs [12](#tjp13730-fig-0012){ref-type="fig"}, [13](#tjp13730-fig-0013){ref-type="fig"} and [16](#tjp13730-fig-0016){ref-type="fig"}), the parameters of the varied currents were randomly determined using the parameter distributions created from the dataset‐specific models. Each parameter was chosen from a distribution centered at the baseline model value. For example, for each cell in the population of models the value of *x* ~1~ is randomly chosen from a normal distribution around *x* ~1,avg~. The normal distribution is created using *x* ~1,avg~ and the SD of *x* ~1A~, *x* ~1B~ and *x* ~1C~, as described above (Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, step 1c). This same process is used to create a distribution for each parameter (*x* ~1--5~) in each model gating variable, as well as for the maximal conductance (*g* ~x~). The populations are constructed by randomly selecting each parameter from these distributions. In the single‐current variation populations, all parameters for the chosen current are randomly determined and the remaining model currents retain the baseline model formulation. In the final population, parameters for all five varied currents (*I* ~Na~, *I* ~CaL~, *I* ~Kr~, *I* ~K1~ and *I* ~f~) are randomly selected from the constructed distributions.

Experimental calcium imaging (Wu Lab) {#tjp13730-sec-0130}
-------------------------------------

iPSC‐CMs were disassociated by Accutase and seeded in Matrigel‐coated (Becton‐Dickinson Biosciences, Franklin Lakes, NJ, USA) coverslips at a density of 20 000 cells well^--1^. After recovery, cells were loaded with 5 µ[m]{.smallcaps} Fura‐2 AM in Tyrode\'s solution (140 m[m]{.smallcaps} NaCl, 5.4 m[m]{.smallcaps} KCl, 1 m[m]{.smallcaps} MgCl~2~, 10 m[m]{.smallcaps} glucose, 1.8 m[m]{.smallcaps} CaCl~2~ and 10 m[m]{.smallcaps} Hepes, pH 7.4, with NaOH at room temperature) for 10 min in incubator, and were then washed with pre‐warmed Tyrode\'s solution three times. Cells were paced at 0.5 Hz during recording. For Fura‐2 AM imaging, calcium signals were sampled using a custom‐made Eclipse Ti‐E inverted microscope (Nikon, Tokyo, Japan) with a 40× oil immersion objective (NA 0.95) and a Lambda DG‐4 ultra‐high speed wavelength switching light source (Sutter Instruments, Novato, CA, USA). Signals were collected with iXon Ultra 897 EMCCD (Andor Technology Ltd, Belfast, UK) as high‐frame‐rate video (512 × 512, 50 frames s^--1^). Custom‐made IDL (interactive digital language) script was used for data analysis. Calcium signal intensity was expressed F340/380 in Fura‐2 AM recording. For each cell line, we recorded at least 30 cells from two batches of differentiation.

Experimental electrophysiology recordings (Kurokawa Lab) {#tjp13730-sec-0140}
--------------------------------------------------------

The methods for *I* ~K1~, *I* ~Na~ and *I* ~f~ experimental data used to optimize the model are as described previously in Li *et al*. ([2017](#tjp13730-bib-0045){ref-type="ref"}). The methodology for the *I* ~CaT~ recordings is described here.

###  {#tjp13730-sec-0150}

#### Cell culture (Kurokawa Lab) {#tjp13730-sec-0160}

We used commercially available human iPS cell (hiPSC)‐derived cardiomyocytes, iCell‐cardiomyocytes (Cellular Dynamics International Japan, Tokyo, Japan). Pre‐cultured iCell‐cardiomyocytes obtained according to the company manual were dissociated enzymatically and were cultured onto laminin/poly‐[d/l]{.smallcaps}‐lysine‐coated glass bottom dishes. These re‐plated cells started to beat within 48 h. Electrophysiological experiments were performed within 2 weeks after thawing because the distributing company (Cellular Dynamics International Japan) warrants preservation of a high purity in the user\'s guide.

#### Electrophysiology (Kurokawa Lab) {#tjp13730-sec-0170}

Membrane currents were recorded with the perforated configuration of the patch clamp technique using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, USA). Signals were low‐pass filtered at 5 kHz, and sampled at 2--5 kHz. No correction for the liquid junction potential was made. pCLAMP, version 9.2 or 10.02 (Molecular Devices, Sunnyvale, CA, USA) was used to generate voltage‐pulse protocols, as well as for acquisition and analysis of data.

Cultured cells were placed on the stage of the inverted microscope (IX‐71; Olympus, Tokyo, Japan) and the culture medium was replaced by a Tyrode\'s solution (135 m[m]{.smallcaps} NaCl/0.33 m[m]{.smallcaps} NaH~2~PO~4~/5.4 m[m]{.smallcaps} KCl/1.8 m[m]{.smallcaps} CaCl~2~/0.53 m[m]{.smallcaps} MgCl~2~/5.5 m[m]{.smallcaps} glucose/5 m[m]{.smallcaps} Hepes, pH 7.4). After the giga‐ohm seal formation, the Tyrode\'s solution was used to replace the external recording solution for each membrane current using a rapid perfusion system (time constant; \>20 ms) (Kurokawa *et al*. [2001](#tjp13730-bib-0041){ref-type="ref"}). Each of the patch clamp data samples was obtained from an individual culture dish. Experiments were performed at 36 ± 1 °C.

During the recordings of *I* ~Ca,T~, external Na^+^ ions and all K^+^ ions were replaced by tetraethyl ammonium (TEA)^+^ and Cs^+^ ions to suppress both Na^+^ currents and K^+^ currents. Pipette solution contained (130 m[m]{.smallcaps} CsCl/20 m[m]{.smallcaps} TEACl/2 m[m]{.smallcaps} MgCl~2~/5 m[m]{.smallcaps} ATP‐2Na/10 m[m]{.smallcaps} Hepes/10 m[m]{.smallcaps} EGTA, pH 7.25), supplemented with amphotericin B. To achieve patch perforation, we front‐filled patch pipettes by dipping them into the internal solution, and back‐filled with the internal solution containing amphotericin B. Adequate series resistances (less than five‐fold of the pipette resistances) were usually attained within 10 min after the gigaohm seal formation. Each current component was determined in each single cell by subtracting the traces after application of channel blocker. Our rapid perfusion system enables us to exchange the bath solution almost immediately, which minimizes the risk of contamination of time‐dependent leak currents.

After achieving membrane perforation, the Tyrode\'s solution was replaced by a Na^+^‐free K^+^‐free solution (135 m[m]{.smallcaps} TEACl/5.4 m[m]{.smallcaps} CsCl/2 m[m]{.smallcaps} CaCl~2~/0.53 m[m]{.smallcaps} MgCl~2~/11 m[m]{.smallcaps} glucose, 5 m[m]{.smallcaps} Hepes, pH 7.4). TTX at 10 µ[m]{.smallcaps} was added to the solution to abolish contamination with low‐threshold activating TTX‐sensitive Ca^2+^ currents (Vassort *et al*. [2006](#tjp13730-bib-0094){ref-type="ref"}). According to a comparison of current‐voltage (*I*--*V*) relationships from −100 mV and −50 mV, *I* ~Ca,T~ currents were elicited by 150 ms test pulses to −30 mV (V~H~ of −100 mV, 0.1 Hz). The obtained inward currents were completely blocked with 0.5 m[m]{.smallcaps} NiCl~2~ (data not shown), representing most of the *I* ~Ca,T~ component. Two representative data points were referred to for optimization of the model.

Results {#tjp13730-sec-0180}
=======

We set out to develop a computational model that can recapitulate the varied electrophysiological responses of iPSC‐CMs. A schematic of the model cell containing all the ionic processes and compartments in the model is shown in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}. The process for determining all ionic current models is described by the flow chart in Fig. [2](#tjp13730-fig-0002){ref-type="fig"}. All major ionic currents (indicated by red stars in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}) were formulated and parameterized to fit iPSC‐CM experimental kinetic data, as detailed in Table [1](#tjp13730-tbl-0001){ref-type="table"}.

Sodium current (*I* ~Na~) {#tjp13730-sec-0190}
-------------------------

The sodium current model contains three Hodgkin--Huxley type gating variables: activation (*m*), fast‐inactivation (*h*) and slow‐inactivation (*j*), as described previously (Beeler & Reuter, [1977](#tjp13730-bib-0002){ref-type="ref"}). The model formulation for the sodium current is shown as the example current in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}. For each gating variable, experimental data from iPSC‐CMs were used to optimize model parameters (*x* ~1--5~). Three distinct dataset‐specific models of the sodium current were optimized, based on three independent experimental datasets. One sodium dataset was from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) and two independent datasets were from the Jalife Lab (Herron *et al*. [2016](#tjp13730-bib-0026){ref-type="ref"}). The immature dataset from the Jalife Lab was collected in iPSC‐CMs plated on glass coverslips (conventional cell preparation). The mature dataset from the Jalife Lab was collected in iPSC‐CMs plated on polydimethylsiloxane (PDMS) coverslips, which were shown to promote mature electrophysiological function in iPSC‐CMs (Herron *et al*. [2016](#tjp13730-bib-0026){ref-type="ref"}). The Jalife Lab data were collected at room temperature. Before optimizing the model parameters, the Jalife Lab experimental data were converted to physiological temperature using *Q* ~10 = ~2.79 for time constants (ten Tusscher *et al*. [2004](#tjp13730-bib-0088){ref-type="ref"}) and *Q* ~10 = ~1.5 for conductance (Correa *et al*. [1991](#tjp13730-bib-0012){ref-type="ref"}). Experimental data shown in Fig. [3](#tjp13730-fig-0003){ref-type="fig"} *C--D* comprise adjusted data with respect to physiological temperature. Experimental iPSC‐CM voltage dependence of steady‐state inactivation and activation data were used to optimized parameters for *h* ~∞~\**j* ~∞~ and *m* ~∞~ ^3^, respectively. The experimental data used for parameterization, as well as the resulting models, are shown in Fig. [3](#tjp13730-fig-0003){ref-type="fig"} *A*.

Several experimentally published datasets from iPSC‐CMs do not contain explicit information for the time constants of gating processes. However, current recording traces were published. To extract time constants of gating kinetics, normalized current recordings from published data were fit to single‐exponential functions (*e* ^−t/^ **^τ^**; *t* = time, **τ** = time constant) for activation and/or inactivation at each voltage step. These extracted time constant values were used to optimize model parameters. In the sodium current, this technique was used to extract activation and fast‐inactivation time constants from sodium current recordings in Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) and Herron *et al*. ([2016](#tjp13730-bib-0026){ref-type="ref"}). The resulting time constant values (corrected to physiological temperature) and respective model fits are shown in Fig. [3](#tjp13730-fig-0003){ref-type="fig"} *C* and *D*. All three dataset‐specific models were optimized to data from the Kurokawa Lab for time constants of slow‐inactivation, as shown in Fig. [3](#tjp13730-fig-0003){ref-type="fig"} *E*. The maximal conductance for each model was tuned to fit the *I*--*V* relationship for the corresponding dataset, as shown in Fig. [3](#tjp13730-fig-0003){ref-type="fig"} *B*. The sodium current kinetics in the baseline iPSC‐CM model are shown in black (Fig. [3](#tjp13730-fig-0003){ref-type="fig"}).

L‐type calcium current (*I* ~CaL~) {#tjp13730-sec-0200}
----------------------------------

The model L‐type calcium current contains voltage‐dependent activation and inactivation gating variables (*x* ~act~, *x* ~inact~). Both gates were modelled using the formulation shown for example gate *x* in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}. The model also includes a calcium‐dependent inactivation gate (*x* ~inact,Ca~) from the ten Tusccher 2004 model. The model L‐type calcium current is described by: $$\begin{array}{ccl}
I_{\text{CaL},y} & = & {p_{\text{CaL},y} \ast x_{\text{act}} \ast x_{\text{inact}} \ast x_{\text{inact},\text{Ca}} \ast z_{y}^{2}} \\
 & & {\ast \,\frac{VF^{2}}{RT}\gamma_{y}\frac{{\lbrack Y\rbrack}_{i}e^{z_{y}\text{VF}/\text{RT}} - {\lbrack Y\rbrack}_{o}}{e^{z_{y}\text{VF}/\text{RT}} - 1}} \\
\end{array}$$

where *y* is Ca^2+^, Na^+^ or K^+^, *p* ~CaL,y~ indicates the permeability to ion *y*, *R* is the gas constant, *z* ~y~ is the valence of ion *y*, and γ~y~ is to activity coefficient for ion *y* as in the Shannon--Bers model. The total current is the sum of the Ca^2+^, Na^+^ and K^+^ currents. $$I_{CaL} = I_{{CaL},{Ca}} + I_{CaL},{Na} + I_{CaL},K$$Parameters for the voltage‐dependent inactivation and activation gates (*x* ~inact~ and *x* ~act~) were optimized to iPSC‐CM experimental steady‐state inactivation and activation curves, as well as voltage‐dependent time constants of inactivation and activation. The four dataset‐specific models were optimized to experimental data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}), Es‐Salah‐Lamoureux *et al*. ([2016](#tjp13730-bib-0018){ref-type="ref"}) and two independent datasets from Veerman *et al*. ([2016](#tjp13730-bib-0095){ref-type="ref"}). Es‐Salah‐Lamoureux *et al*. ([2016](#tjp13730-bib-0018){ref-type="ref"}) and Veerman *et al*. ([2016](#tjp13730-bib-0095){ref-type="ref"}) used an in‐house iPSC‐CM line for experimental results shown. *I* ~CaL~ recordings by Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) and Es‐Salah‐Lamoureux *et al*. ([2016](#tjp13730-bib-0018){ref-type="ref"}) were conducted at room temperature and converted to physiological temperature using *Q* ~10~ = 2.1 for time constants (ten Tusscher *et al*. [2004](#tjp13730-bib-0088){ref-type="ref"}) and *Q* ~10~ = 2.3 for conductance (Kiyosue *et al*. [1993](#tjp13730-bib-0039){ref-type="ref"}).

Steady‐state inactivation and activation iPSC‐CM experimental data, as well as optimized dataset‐specific models for each dataset, are shown in Fig. [4](#tjp13730-fig-0004){ref-type="fig"} *A*. As a result of a lack of explicitly reported experimental iPSC‐CM data for the time constants of voltage‐dependent L‐type calcium gating, time constants were extracted from current recordings by Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) (as described above for the sodium current). The time constants in Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}), corrected to physiological temperature, were used to optimize all models. The experimental conditions for calcium buffering during the *I* ~CaL~ current recordings by Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) (5 m[m]{.smallcaps} EGTA), may result in some calcium‐dependent inactivation contribution to the time constants of inactivation derived from these current recordings. Because this calcium‐dependent inactivation contribution was not quantified experimentally, the time constants of inactivation derived from the current recordings were assumed to be entirely voltage‐dependent inactivation for model parameterization. The time constant data used for model optimization, and the resulting models, are shown in Fig. [4](#tjp13730-fig-0004){ref-type="fig"} *C* and *D*.

The calcium‐dependent inactivation gate (*x* ~inact,Ca~) formulation in the ten Tusscher 2004 model was retained in this model as a result of a lack of experimental data characterizing calcium‐dependent inactivation in iPSC‐CMs. A single scaling factor for \[Ca\]~i~ in $x_{{inact},{Ca},\infty}$ was optimized in the final whole‐cell parameter optimization to recapitulate iPSC‐CM calcium handling. This was required to accommodate the lower \[Ca\]~i~ throughout the iPSC‐CM AP compared to the adult ventricular cell model in the ten Tusscher 2004 model. Figure [4](#tjp13730-fig-0004){ref-type="fig"} shows all of the *I* ~CaL~ models with the final optimized calcium‐dependent inactivation gate.

Values for γ~Ca~, γ~Na~ and γ~K~, and the relative proportions of p~CaL,Ca~:p~CaL,Na~:p~CaL,K~ were retained from the Shannon--Bers model (Shannon *et al*. [2004](#tjp13730-bib-0083){ref-type="ref"}). The total permeability (p~CaL~ = p~CaL,Ca~ + p~CaL,Na~ + p~CaL,K~) of each dataset‐specific model was tuned using the experimental *I*--*V* curves and the resulting *I*--*V* relationships are shown in Fig. [4](#tjp13730-fig-0004){ref-type="fig"} *B*. The baseline model for *I* ~CaL~ is shown in black in Fig. [4](#tjp13730-fig-0004){ref-type="fig"}.

T‐type calcium current (*I* ~CaT~) {#tjp13730-sec-0210}
----------------------------------

The T‐type calcium current was introduced to the iPSC‐CM model because it is experimentally found in iPSC‐CMs. T‐type calcium is typically found in embryonic hearts and its expression is dependent on the developmental stage of the heart (Ono & Iijima, [2010](#tjp13730-bib-0066){ref-type="ref"}). T‐type calcium is also found experimentally in iPSC‐CMs (Ivashchenko *et al*. [2013](#tjp13730-bib-0031){ref-type="ref"}; Karakikes *et al*. [2015](#tjp13730-bib-0036){ref-type="ref"}), as is expected as a result of the iPSC‐CMs immature cardiac phenotype. The T‐type calcium current was modelled as in the previously published sinoatrial node model by Maltsev & Lakatta ([2009](#tjp13730-bib-0052){ref-type="ref"}). Peak *I* ~CaT~ was tuned to the *I*--*V* curves for *I* ~CaT~ provided by the Kurokawa Lab, as shown in Fig. [4](#tjp13730-fig-0004){ref-type="fig"} *E*.

Rapid delayed rectifier potassium current (*I* ~Kr~) {#tjp13730-sec-0220}
----------------------------------------------------

The rapid delayed rectifier potassium current was modelled as: $$I_{Kr} = g_{Kr} \ast \sqrt{\frac{K_{0}}{5.4}} \ast x_{act} \ast x_{inact} \ast \left( {V_{m} - E_{K}} \right)$$

The voltage‐dependent activation and inactivation gating variables (*x* ~act~, *x* ~inact~) were modelled using the formulation shown for the exemplar gate *x* in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}. The *K* ~o~ dependence of the current ($\sqrt{K_{o}/5.4}$) and the voltage‐dependent inactivation gate was retained from the ten Tusscher 2004 formulation of *I* ~Kr~. To utilize the simplified gating model formulation for the *I* ~Kr~ inactivation gate (*x* ~inact~), the single‐exponential voltage‐dependent rate constant model (Fig. [1](#tjp13730-fig-0001){ref-type="fig"}, right) was optimized to fit the voltage‐dependence of *I* ~Kr~ inactivation in the ten Tusscher 2004 model. The resulting model of inactivation gating is shown in Fig. [5](#tjp13730-fig-0005){ref-type="fig"} *A* and *D*.

Dataset‐specific models of steady‐state activation were fit to four independent iPSC‐CM experimental datasets from the Wu Lab (Garg *et al*. [2018](#tjp13730-bib-0020){ref-type="ref"}), as well as from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}), Bellin *et al*. ([2013](#tjp13730-bib-0004){ref-type="ref"}) and Es‐Salah‐Lamoureux *et al*. ([2016](#tjp13730-bib-0018){ref-type="ref"}). The data by Es‐Salah‐Lamoureux *et al*. ([2016](#tjp13730-bib-0018){ref-type="ref"}) were collected from an in‐house iPSC‐CM line and the data by Bellin *et al*. ([2013](#tjp13730-bib-0004){ref-type="ref"}) were collected from a patient‐specific cell line. Voltage‐dependent time constants of activation were extracted from current recordings published in Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}). The time constants of activation in Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) were used to optimize parameters in the optimized models of Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}), the Wu Lab (Garg *et al*. [2018](#tjp13730-bib-0020){ref-type="ref"}) and Es‐Salah‐Lamoureux *et al*. ([2016](#tjp13730-bib-0018){ref-type="ref"}). Experimental time constants of activation were published in Bellin *et al*. ([2013](#tjp13730-bib-0004){ref-type="ref"}) and used in the corresponding model, as shown in green in Fig. [5](#tjp13730-fig-0005){ref-type="fig"} *C*. Finally, the maximal conductance (g~Kr~) of each dataset‐specific model was tuned to the *I*--*V* relationship data for each dataset, shown in Fig. [5](#tjp13730-fig-0005){ref-type="fig"} *B*. Bellin *et al*. ([2013](#tjp13730-bib-0004){ref-type="ref"}) published a single data point for the experimental *I*--*V* relationship (at V~m~ = 60 mV, not shown), which was used to optimize the maximal conductance of the corresponding model.

Transient outward potassium current (*I* ~to~) {#tjp13730-sec-0230}
----------------------------------------------

The transient outward potassium current was modelled as: $$I_{to} = g_{to} \ast x_{act} \ast x_{inact} \ast \left( {V_{m} - E_{K}} \right)$$The voltage‐dependent activation and inactivation gating variables (*x* ~act~, *x* ~inact~) were modelled using the formulation of example gate *x* in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}. iPSC‐CM experimental data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}), Cordeiro *et al*. ([2013](#tjp13730-bib-0011){ref-type="ref"}) and Veerman *et al*. ([2016](#tjp13730-bib-0095){ref-type="ref"}) were used to optimize dataset‐specific models. Experimental results in Veerman *et al*. ([2016](#tjp13730-bib-0095){ref-type="ref"}) were recorded in an in‐house iPSC‐CM cell‐line. Steady‐state activation and time constants of inactivation were extrapolated from *I* ~to~ current recordings published in Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}). Time constants of inactivation from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) were used to optimize the inactivation time constant parameters of the model by Veerman *et al*. ([2016](#tjp13730-bib-0095){ref-type="ref"}). Steady‐state activation data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) were used to optimize the model of Cordeiro *et al*. ([2013](#tjp13730-bib-0011){ref-type="ref"}) and steady‐state inactivation data from Cordeiro *et al*. ([2013](#tjp13730-bib-0011){ref-type="ref"}) were used to optimize the model of Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) because neither dataset included both steady‐state activation and inactivation data.

Time constants for activation of *I* ~to~ were not available in iPSC‐CMs; thus, model parameters were optimized to retain the ten Tusscher 2004 voltage‐dependence for time constants of activation. The resulting model for time constants of *I* ~to~ activation are shown in Fig. [6](#tjp13730-fig-0006){ref-type="fig"} *C*. Finally, maximal conductance (*g* ~to~) was tuned to experimental iPSC‐CM *I*--*V* relationships for each dataset, as shown in Fig. [6](#tjp13730-fig-0006){ref-type="fig"} *B*.

Slow delayed rectifier potassium current (*I* ~Ks~) {#tjp13730-sec-0240}
---------------------------------------------------

The slow delayed rectifier potassium current was modelled as: $$I_{Ks} = g_{Ks} \ast x_{act}^{2} \ast \left( {V_{m} - E_{K}} \right)$$The voltage‐dependent activation gating variable (*x* ~act~) was modelled using the formulation of example gate *x* in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}. Dataset‐specific models were optimized to experimental data from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) and two independent datasets from Ma *et al*. ([2015](#tjp13730-bib-0050){ref-type="ref"}), shown in Fig. [7](#tjp13730-fig-0007){ref-type="fig"} *A* (Ma *et al*. [2011](#tjp13730-bib-0051){ref-type="ref"}; Ma *et al*. [2015](#tjp13730-bib-0050){ref-type="ref"}). Ma *et al*. ([2015](#tjp13730-bib-0050){ref-type="ref"}) recorded one *I* ~Ks~ dataset in a patient‐specific iPSC‐CM cell‐line, and another dataset in iCell iPSC‐CMs. Parameters for $x_{{act},\infty}^{2}$ were optimized to steady‐state activation data, as shown in Fig. [7](#tjp13730-fig-0007){ref-type="fig"} *A*. As a result of a lack of available experimental data for the time constants of *I* ~Ks~ activation, time constants extracted from current recordings published in Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) were used to optimize parameters in all models, as shown in Fig. [7](#tjp13730-fig-0007){ref-type="fig"} *B*. Finally, the maximal conductance (g~Ks~) was tuned to *I*--*V* data, as shown in Fig. [7](#tjp13730-fig-0007){ref-type="fig"} *C*. For both models built on datasets of Ma *et al*. ([2015](#tjp13730-bib-0050){ref-type="ref"}) (Fig. [7](#tjp13730-fig-0007){ref-type="fig"}, patient‐specific in orange, iCell in purple), the maximal conductance was tuned to the *I*--*V* relationship in iCells of Ma *et al*. ([2015](#tjp13730-bib-0050){ref-type="ref"}), as shown by purple points in Fig. [7](#tjp13730-fig-0007){ref-type="fig"} *C*.

Pacemaker/funny current (*I* ~f~) {#tjp13730-sec-0250}
---------------------------------

The pacemaker current was incorporated into the iPSC‐CM model, as it is experimentally found in iPSC‐CMs (Karakikes *et al*. [2015](#tjp13730-bib-0036){ref-type="ref"}; Kim *et al*. [2015](#tjp13730-bib-0038){ref-type="ref"}). The current was formulated as: $$I_{f} = g_{F} \ast x_{act} \ast \left( {V_{m} - E_{f}} \right)$$where *E* ~f~ and *g* ~f~ are calculated as a balance of the sodium and potassium Nernst potentials (Verkerk & Wilders, [2013](#tjp13730-bib-0096){ref-type="ref"}), such that: $$g_{f}{({V_{m} - E_{f}})} = g_{f,{Na}}{({V_{m} - E_{Na}})} + g_{f,K}{({V_{m} - E_{K}})}\qquad$$where the ratio of *g~f~* ~,Na~:*g* ~f,K~ = 0.491, based on prior models of *I* ~f~ in rabbit sinoatrial node (Verkerk & Wilders, [2013](#tjp13730-bib-0096){ref-type="ref"}). The activation gate (*x* ~act~) is modelled using the same formulation as example gate x in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}. Experimental data in iPSC‐CMs from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}) and the Kurokawa Lab (Li *et al*. [2017](#tjp13730-bib-0045){ref-type="ref"}) were used to optimize dataset‐specific models. Model parameters for the activation gate (x~act~) were optimized to experimental data for steady‐state activation and time constants of activation, as shown in Fig. [8](#tjp13730-fig-0008){ref-type="fig"} *A* and *B*. Maximal conductances (*g* ~f~) for each dataset‐specific model were fit to *I*--*V* relationships of the corresponding experimental dataset. The experimental data and resulting models are shown in Fig. [8](#tjp13730-fig-0008){ref-type="fig"} *C*.

Inward rectifier potassium current (*I* ~K1~) {#tjp13730-sec-0260}
---------------------------------------------

The slow delayed rectifier potassium current was modelled as: $$I_{K1} = g_{K1}\sqrt{\frac{K_{0}}{5.4}} \ast x_{{act},\infty} \ast \left( {V_{m} - E_{K}} \right)$$The *K* ~o~ dependence of the current ($\sqrt{K_{o}/5.4}$) is retained from the ten Tusscher 2004 formulation of *I* ~K1~. To recapitulate the behaviour of *I* ~K1~, the activation gate was formulated as: $$\alpha_{x} = x_{1}e^{{({V + x_{3}})}/x_{2}}$$ $$\beta_{x} = e^{{({V + x_{5}})}/x_{4}}$$

Dataset‐specific models were created by optimizing parameters *x* ~1--5~ and *g* ~K1~ to the *I*--*V* relationships recorded in iPSC‐CMs from Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}), the Kurokawa Lab (Li *et al*. [2017](#tjp13730-bib-0045){ref-type="ref"}) and the Jalife Lab (Herron *et al*. [2016](#tjp13730-bib-0026){ref-type="ref"}). Experimental data from the Jalife Lab were collected at room temperature. The Jalife Lab *I*--*V* curves were corrected to physiological temperature using *Q* ~10~ = 1.5 (Kiyosue *et al*. [1993](#tjp13730-bib-0039){ref-type="ref"}). The experimental data used to optimize the models, and the resulting models are shown in Fig. [9](#tjp13730-fig-0009){ref-type="fig"}.

Pump and exchanger currents (*I* ~NCX~, *I* ~NaK~, *I* ~PMCA~) {#tjp13730-sec-0270}
--------------------------------------------------------------

To model the remaining membrane currents which are not characterized in iPSC‐CMs, we utilized previous models. The sodium‐calcium exchanger (*I* ~NCX~), sodium potassium pump (*I* ~NaK~) and sarcolemma pump (*I* ~PMCA~) currents were modelled using formulations from prior ventricular cell models (Luo & Rudy, [1994](#tjp13730-bib-0049){ref-type="ref"}; ten Tusscher *et al*. [2004](#tjp13730-bib-0088){ref-type="ref"}). Kinetics of these currents were retained from existing ventricular cell models because these currents have not been characterized experimentally in iPSC‐CMs. Maximal values of all three currents were included in the whole‐cell optimization routine (Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, step 2) and the final parameterizations are detailed in Table [3](#tjp13730-tbl-0003){ref-type="table"}. $$\begin{array}{r}
{I_{NCX} = k_{NCX} \ast \frac{\left( {e^{{\gamma{VF}}/{RT}} \ast {{\lbrack Na\rbrack}_{i}}^{3} \ast \left\lbrack {Ca} \right\rbrack_{o}} \right) - \left( {e^{\frac{{({\gamma - 1})}{VF}}{RT}} \ast {{\lbrack Na\rbrack}_{o}}^{3} \ast \left\lbrack {Ca} \right\rbrack_{i} \ast \alpha} \right)}{\left( {{K_{mNa}}^{3} + {{\lbrack Na\rbrack}_{o}}^{3}} \right) \ast \left( {K_{mCa} + \left\lbrack {Ca} \right\rbrack_{o}} \right) \ast \left( {1 + k_{sat} \ast e^{\frac{{({\gamma - 1})}{VF}}{RT}}} \right)}} \\
\end{array}$$ $$\begin{array}{ccl}
 & & I_{NaK} \\
 & & {\quad = \frac{P_{NaK} \ast {\lbrack K\rbrack}_{o} \ast {\lbrack{Na}\rbrack}_{i}}{{({{\lbrack K\rbrack}_{o} + K_{mK}})} \ast {({{\lbrack{Na}\rbrack}_{i} + K_{mNa}})} \ast {({1 + 0.1245 \ast e^{\frac{- 0.1{\ast {VF}}}{RT}} + 0.0353 \ast e^{\frac{- {VF}}{RT}}})}}} \\
\end{array}$$ $$I_{PMCA} = g_{PMCA} \ast \frac{\left\lbrack {Ca} \right\rbrack_{i}}{\left( {\left\lbrack {Ca} \right\rbrack_{i} + K_{PMCA}} \right)}$$

SR currents (*J* ~Rel~, *J* ~up~, *J* ~leak~) {#tjp13730-sec-0280}
---------------------------------------------

The calcium handling in iPSC‐CMs has not been fully characterized experimentally. Thus, the calcium handling in the present model is based on prior formulations of SR currents. Parameters for the RYR (*J* ~rel~) were adapted from the Shannon--Bers model to maintain physiological SR function during the beating cycle. The Shannon--Bers RYR formulation is dependent on the high calcium concentration in the cleft compartment described in the Shannon--Bers cellular geometry. However, the geometry used in the present model does not include this cleft compartment (as shown schematically in Fig. [1](#tjp13730-fig-0001){ref-type="fig"}). Given these differences in cellular geometry, the original Shannon--Bers *J* ~Rel~ parameters do not produced a SR release during the AP in the simplified cellular geometry used in this model. To implement the Shannon--Bers RYR Markov model formulation within the cellular geometry described above, RYR transition rates were determined by our whole‐cell optimization routine (Fig. [2](#tjp13730-fig-0002){ref-type="fig"}, Step 2). Maximal values of *J* ~up~ and *J* ~leak~ were also included in the whole‐cell optimization. Final parameterizations of all SR currents are detailed in Table [3](#tjp13730-tbl-0003){ref-type="table"}. $$J_{up} = \frac{V_{\max,{up}}}{\left( {1 + \frac{{K_{up}}^{2}}{{\left\lbrack {Ca} \right\rbrack_{i}}^{2}}} \right)}$$ $$J_{leak} = V_{leak} \ast \left( {\left\lbrack {Ca} \right\rbrack_{SR} - \left\lbrack {Ca} \right\rbrack_{i}} \right)$$

For closed (*C*), open (*O*), inactivated (*I*) and closed‐inactivated (*CI*) states of *J* ~Rel~: $$CI = 1 - C - O - I$$ $$\begin{array}{ccl}
\frac{dC}{dt} & = & \left( {k_{im} \ast CI - k_{iSRCa} \ast \left\lbrack {Ca} \right\rbrack_{i} \ast C} \right) \\
 & & {- \,\left( {k_{oSRCa} \ast {\left\lbrack {Ca} \right\rbrack_{i}}^{2} \ast C - k_{om} \ast O} \right)} \\
\end{array}$$ $$\begin{array}{ccl}
\frac{dO}{dt} & = & \left( {k_{oSRCa} \ast {\left\lbrack {Ca} \right\rbrack_{i}}^{2} \ast C - k_{om} \ast O} \right) \\
 & & {- \,\left( {k_{iSRCa} \ast \left\lbrack {Ca} \right\rbrack_{i} \ast O - k_{im} \ast I} \right)} \\
\end{array}$$ $$\begin{array}{ccl}
\frac{dI}{dt} & = & \left( {k_{iSRCa} \ast \left\lbrack {Ca} \right\rbrack_{i} \ast O - k_{im} \ast I} \right) \\
 & & {- \,\left( {k_{om} \ast I - k_{oSRCa} \ast {\left\lbrack {Ca} \right\rbrack_{i}}^{2} \ast CI} \right)} \\
\end{array}$$ $$J_{Rel} = k_{s} \ast O \ast \left( {\left\lbrack {Ca} \right\rbrack_{SR} - \left\lbrack {Ca} \right\rbrack_{i}} \right) \ast \frac{V_{SR}}{V_{C}}$$

Model development: intracellular Ca^2+^ dynamics {#tjp13730-sec-0290}
------------------------------------------------

Figure [10](#tjp13730-fig-0010){ref-type="fig"} *A* shows the baseline model (red) calcium transient compared to experimental CaTs from the Wu Lab (grey). Experimental CaTs shown are reported as a florescence ratio (*F* ~ratio~), as plotted in Fig. [10](#tjp13730-fig-0010){ref-type="fig"} *A* on the right *y*‐axis. The average peak *F* ~ratio~ value of the dataset shown (Peak *F* ~ratio~ = 4.25) corresponds to the independently measured iPSC‐CM average peak CaT concentration (Fig. [10](#tjp13730-fig-0010){ref-type="fig"} *B*) on the left *y*‐axis. Similarly, the diastolic *F* ~ratio~ value (Diastolic *F* ~ratio~ = 0) also corresponds to the independently measured iPSC‐CM average diastolic CaT concentration (Fig. [10](#tjp13730-fig-0010){ref-type="fig"} *B*).

![Optimization of calcium handling in the iPSC‐CM baseline model\
*A*, experimental iPSC‐CM CaT traces from the Wu lab (grey) (Garg *et al*. [2018](#tjp13730-bib-0020){ref-type="ref"}) with baseline model CaT (red). Experimental data were reported as the normalized Ca^2+^ florescence (*F* ~ratio~). Separately, average iPSC‐CM peak and diastolic Ca^2+^ concentrations were measured by the Wu lab. The two *y*‐axes are plotted so that the average F~ratio~ peak and diastolic values of the experimental dataset shown correspond to the average experimental concentration of peak and diastolic Ca^2+^ (*B*). The baseline model CaT output is n[m]{.smallcaps}. *B*, comparison of baseline model CaT morphology markers with experimental iPSC‐CM data from the Wu lab. *C*, relative contribution of calcium from *I* ~SERCA~, *I* ~NCX~ and *I* ~PMCA~ to the CaT during a single AP in the baseline model. *D*, comparison of experimental (black and white) and baseline model (coloured) relative contribution of calcium flux from *I* ~SERCA~, *I* ~NCX~ and *I* ~PMCA~ during the CaT. Experimental data from Hwang *et al*. ([2015](#tjp13730-bib-0029){ref-type="ref"}).](TJP-597-4533-g011){#tjp13730-fig-0010}

To reproduce the CaT data described above, SR currents (*J* ~Up~, *J* ~Rel~ and *J* ~leak~) and calcium‐dependent transmembrane currents that were not previously parameterized to fit iPSC‐CM data (*I* ~NCX~, *I* ~PMCA~) were optimized to recapitulate the experimentally observed iPSC‐CM CaT morphology shown in Fig. [10](#tjp13730-fig-0010){ref-type="fig"} *B*. The baseline model parameters were optimized to produce CaT outputs within 1 SD of the experimental Ca^2+^ transient markers shown. Additionally, the optimization considered the ratio of time to peak and time constant of decay of the CaT. The baseline model has a faster spontaneous beating rate (62.0 beats min^--1^) than the average spontaneous beating rate in the CaT dataset from the Wu Lab (30.2 ± 13.2 beats min^--1^). To normalize the experimental data and account for this difference in pacing rate, we included the ratio of the CaT time to peak and CaT time constant of decay as a target in our optimization error function. The ratio of the time to peak and time constant of decay of the experimental CaT was 0.83, and the resulting baseline model CaT ratio is 0.77. Thus, the model recapitulates the relative portion a single AP cycle spent at each phase of the CaT.

The model was also tuned to recapitulate the relative contribution of three fluxes (*I* ~NCX~, *J* ~Up~ and *I* ~PMCA~) to the calcium removal pathways (Fig. [10](#tjp13730-fig-0010){ref-type="fig"} *C* and *D*) (Hwang *et al*. [2015](#tjp13730-bib-0029){ref-type="ref"}). Experimentally, the contribution of NCX (*I* ~NCX~), SERCA (*J* ~Up~) and the sarcolemma pump (*I* ~PMCA~) is calculated using the time constant of the CaT during a normal AP, the caffeine‐induced CaT and the caffeine‐induced CaT in a sodium and calcium‐free solution (Bers, [2000](#tjp13730-bib-0005){ref-type="ref"}). Hwang *et al*. ([2015](#tjp13730-bib-0029){ref-type="ref"}) provided a comparison of the relative contributions *I* ~NCX~, *J* ~Up~ and *I* ~PMCA~ to the calcium flux balance from six independent iPSC‐ CM datasets across three laboratories. Maximal *I* ~NCX~, *J* ~Up~ and *I* ~PMCA~ in the baseline model were optimized to fit the relative contributions of each current. The relative contribution to the calcium flux in the model was calculated based on the integral of each current during a single CaT. This integral, normalized to total calcium contribution from all three sources, is shown in Fig. [10](#tjp13730-fig-0010){ref-type="fig"} *C* for a single beat in the baseline model, obtained after achieving steady‐state. The resulting relative contributions to calcium flux pathways in the model are comparable to the experimentally observed ranges (Fig. [10](#tjp13730-fig-0010){ref-type="fig"} *D*).

Model prediction: whole cell simulations {#tjp13730-sec-0300}
----------------------------------------

The baseline model that was developed via the steps described above recapitulates the phenotype of typical iPSC‐CMs (Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *A*). The AP and CaT outputs fall within the experimental range of behaviours (Figs [10](#tjp13730-fig-0010){ref-type="fig"} and [11](#tjp13730-fig-0011){ref-type="fig"}). Experimental details of the AP datasets used are described in Table [2](#tjp13730-tbl-0002){ref-type="table"}. The baseline model was optimized to reproduce these key features of the immature iPSC‐CM phenotype, including spontaneous beating (Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *A* and *C*), a reduced AP amplitude (Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *B*), a low maximal upstroke velocity (Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *C*) and a depolarized maximum diastolic potential (MDP) (Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *D*). For precise definitions of AP morphology markers, see the Methods. The baseline model also spontaneously beats during total *I* ~Na~ and *I* ~f~ block, showing that the mechanism of automaticity in the baseline model is consistent with the experimentally observed mechanism (Guo *et al*. [2011](#tjp13730-bib-0024){ref-type="ref"}; Itzhaki *et al*. [2011](#tjp13730-bib-0030){ref-type="ref"}; Sheng *et al*. [2012](#tjp13730-bib-0084){ref-type="ref"}; Kim *et al*. [2015](#tjp13730-bib-0038){ref-type="ref"}). Sensitivity analysis on the baseline model was conducted using a multivariable regression model (Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *E*) (Sobie, [2009](#tjp13730-bib-0085){ref-type="ref"}). The sensitivity analysis shows several expected results for cardiac cells such as increased upstroke velocity with increased sodium current, APD shortening with increased *I* ~Kr~ and APD lengthening with increased *I* ~CaL~. Additionally, increased *I* ~K1~ is experimentally shown to hyperpolarize iPSC‐CM MDP (Bett *et al*. [2013](#tjp13730-bib-0006){ref-type="ref"}; Vaidyanathan *et al*. [2016](#tjp13730-bib-0092){ref-type="ref"}), which is consistent with the results of this sensitivity analysis (Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *E*) showing that increased *I* ~K1 ~hyperpolarizes the cells (indicated by a positive regression coefficient for *I* ~K1~ related to the absolute value of MDP).

![Characterization of the baseline model AP\
*A*, time course of the spontaneously beating APs in the baseline model. *B*--*D*, comparison of AP morphology in the baseline model (red) and experimental iPSC‐CM data (black). Experimental data from the Wu Lab (Garg *et al*. [2018](#tjp13730-bib-0020){ref-type="ref"}), the Jalife Lab (Herron *et al*. [2016](#tjp13730-bib-0026){ref-type="ref"}), Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"}), Doss *et al*. ([2012](#tjp13730-bib-0016){ref-type="ref"}), Cordeiro *et al*. ([2013](#tjp13730-bib-0011){ref-type="ref"}), Es‐Salah‐Lamoureux *et al*. ([2016](#tjp13730-bib-0018){ref-type="ref"}) and Ma *et al*. ([2015](#tjp13730-bib-0050){ref-type="ref"}). *E*, sensitivity analysis using multivariable regression in the baseline model. Only parameters with regression coefficients \>0.3 are shown.](TJP-597-4533-g012){#tjp13730-fig-0011}

###### 

Details for experimental action potential datasets

  Reference                                                                Cell‐line   *n* =  Cell‐type
  ----------------------------------------------------------------------- ----------- ------- --------------------
  Wu Lab (A) (Garg *et al*. [2018](#tjp13730-bib-0020){ref-type="ref"})       IHC       14    Ventricular‐like
  Wu Lab (B) (Garg *et al*. [2018](#tjp13730-bib-0020){ref-type="ref"})       IHC       12    Ventricular‐like
  Herron *et al*. (2016) (PDMS -- Mature)                                    iCell      24    Mixed morphologies
  Herron *et al*. (2016) (Glass -- Immature)                                 iCell      37    Mixed morphologies
  Ma *et al*. ([2011](#tjp13730-bib-0051){ref-type="ref"})                   iCell      32    Ventricular‐like
  Doss *et al*. (2012) (Group A)                                             iCell      63    Ventricular‐like
  Doss *et al*. (2012) (Group B)                                             iCell      23    Ventricular‐like
  Cordeiro *et al*. (2013)                                                   iCell      149   Mixed morphologies
  Es‐Salah‐Lamoureux *et al*. (2016)                                          IHC        9    Ventricular‐like
  Ma *et al*. ([2015](#tjp13730-bib-0050){ref-type="ref"})                    IHC       17    Ventricular‐like

^\*^IHC, in‐house control cell‐line.

John Wiley & Sons, Ltd.

###### 

Model parameter details for pumps, exchangers, and SR currents

  Parameter                                                          Value                                                                 Units              Definition
  -------------- ------------------------------------------------------------------------------------------------------------- ------------------------------ --------------------------------------------------------------------------
  *k* ~NCX~                                                          1100                                                                pA pF^−1^            Maximal *I* ~NCX~
  γ                                                                   0.7                                                                    --               Voltage‐dependence parameter (*I* ~NCX~)
  *K* ~mCa~                                                          1.38                                                             m[m]{.smallcaps}        Ca~i~ half‐saturation parameter (*I* ~NCX~)
  *K* ~mNa~                                                          87.5                                                             m[m]{.smallcaps}        Na~i~ half‐saturation parameter (*I* ~NCX~)
  *k* ~sat~                                                           0.1                                                                    --               Saturation factor (*I* ~NCX~)
  α                                                                  2.75                                                                    --               Outward enhancing factor (*I* ~NCX~)
  *P* ~NaK~                                                          2.48                                                                pA pF^−1^            Maximal *I* ~NaK~
  *K* ~mK~                                                            1.0                                                             m[m]{.smallcaps}        *K* ~o~ half‐saturation parameter (*I* ~NaK~)
  *K* ~mNa~                                                          40.0                                                             m[m]{.smallcaps}        Na~i~ half‐saturation parameter (*I* ~NaK~)
  *g* ~PMCA~                                                        0.2625                                                               nS pF^−1^            Maximal *I* ~PMCA~ conductance
  *K* ~PMCA~                                                        0.0005                                                            m[m]{.smallcaps}        Ca~i~ half‐saturation parameter (*I* ~PMCA~)
  *k* ~s~                                                            12.5                                                                  ms^−1^             SR release rate constant (*I* ~Rel~)
  *k* ~oCa~                                                         643 750                                                     m[m]{.smallcaps} ^−2^ ms^−1^  Non‐SR‐dependent transition rate constant (*J* ~Rel~)
  *k* ~om~                                                          0.2143                                                                 ms^−1^             *J* ~Rel~ rate constant
  *k* ~iCa~                                                         18.495                                                      m[m]{.smallcaps} ^−1^ ms^−1^  Non‐SR‐dependent transition rate constant (*J* ~Rel~)
  *k* ~im~                                                          0.00056                                                                ms^−1^             *J* ~Rel~ rate constant
  EC~50‐SR~                                                          0.45                                                                    --               Parameters for \[Ca\]~SR~‐dependent activation of SR release (*J* ~Rel~)
  Max~SR~                                                             15                                                                     --               
  Min~SR~                                                              1                                                                     --               
  *k* ~CaSR~      $Max_{SR} - \frac{({Max_{SR} - Min_{SR}})}{1 + {(\frac{EC_{50 - {SR}}}{{\lbrack{Ca}\rbrack}_{SR}})}^{2.5}}$                                 \[Ca\]~SR~‐dependent RyR activation coefficient (*J* ~Rel~)
  *k* ~oSRCa~                                             $\frac{k_{oCa}}{k_{CaSR}}$                                                                          *J* ~Rel~ rate constant
  k~iSRCa~                                                  $k_{iCa} \ast k_{CaSR}$                                                                           *J* ~Rel~ rate constant
  *V* ~max,up~                                                  1.105 × 10^--4^                                                   m[m]{.smallcaps} ms^−1^     Maximal *J* ~up~
  *K* ~up~                                                      1.755 × 10^--4^                                                       m[m]{.smallcaps}        Half‐saturation constant
  *V* ~leak~                                                     1.6 × 10^--6^                                                             ms^−1^             Maximal *J* ~leak~
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Although Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *B--D* shows that the baseline model falls within the experimental range, the compilation of experimental data sources also serves to illustrate the vast range of AP behaviour in 'normal' iPSC‐CMs. This range of experimentally observed behaviours reveals that a single 'average' iPSC‐CM model is insufficient to describe the behaviour of iPSC‐CMs, and that variability may be the defining characteristic.

Model prediction: inter‐subject variability {#tjp13730-sec-0310}
-------------------------------------------

To model heterogeneity in kinetic behaviour in healthy iPSC‐CMs, a population‐based approach was utilized. The goal of this approach was to harness the range of experimentally observed kinetics in each ionic current and create an *in silico* population of model cells that captured the full range of iPSC‐CM kinetic behaviour.

A population of models was developed to incorporate experimentally measured kinetic variability in five of the reformulated ionic currents that were identified in the multivariable regression sensitivity analysis as most important to AP behaviour (Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *E*). The five currents were *I* ~Na~, *I* ~CaL~, *I* ~Kr~, *I* ~f~ and I~K1~. The regression coefficients for *I* ~f~ were below the threshold for Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *E*, although *I* ~f~ did impact MDP and BPM in the model but at a lower level than the other currents shown in Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *E*. *I* ~NaK~ was identified by the sensitivity analysis but, as a result of the lack of experimental iPSC‐CM data characterizing the range of kinetic behaviour in *I* ~NaK~, it was not included in the population‐based variability.

In total, six populations were developed. In five of those populations, model parameters for a single current were varied and all the other currents were kept at the baseline values. The populations capture inter‐subject variability observed in the measured electrophysiology data. In the final population, the parameters were simultaneously varied for all five of the identified currents.

To simulate model cell variability, ionic current models were randomly parameterized within the experimentally observed ranges from multiple data sets for steady‐state gating, time constants of gating and *I*--*V* relationships. Using the mean ± SD of each parameter value across the independent dataset‐specific models, a normal distribution was created for each parameter value, as described in further detail in the Methods and Fig. [2](#tjp13730-fig-0002){ref-type="fig"}. For each model cell within the population, parameters were randomly chosen from this distribution. Thus, every model cell in the population has a unique parameter‐set chosen from the normal distribution of underlying parameters composing a single current. The range of kinetic behaviours are shown for populations with single current variation in *I* ~Na~ (Fig. [12](#tjp13730-fig-0012){ref-type="fig"} *A*), *I* ~CaL~ (Fig. [12](#tjp13730-fig-0012){ref-type="fig"} *B*), *I* ~Kr~ (Fig. [12](#tjp13730-fig-0012){ref-type="fig"} *C*), *I* ~f~ (Fig. [12](#tjp13730-fig-0012){ref-type="fig"} *D*) and *I* ~K1~ (Fig. [12](#tjp13730-fig-0012){ref-type="fig"} *E*). Steady‐state and time constant values functions shown in Fig. [12](#tjp13730-fig-0012){ref-type="fig"} are the results of random variation in the parameter values of each of the selected five currents. These randomly determined kinetics result in the whole‐cell behaviour shown in Fig. [13](#tjp13730-fig-0013){ref-type="fig"}.

![Kinetic variability generated by varying individual current model parameters\
Steady‐state and time constant curves for each gate in (*A*) *I* ~Na~, (*B*) *I* ~CaL~, (*C*) *I* ~Kr~ and (*D*) *I* ~f~. *E*, *I*--*V* curves for *I* ~K1~. Dataset‐specific model fits (black lines, also shown in Figs [3](#tjp13730-fig-0003){ref-type="fig"}, [4](#tjp13730-fig-0004){ref-type="fig"}, [5](#tjp13730-fig-0005){ref-type="fig"}, [6](#tjp13730-fig-0006){ref-type="fig"}, [7](#tjp13730-fig-0007){ref-type="fig"}, [8](#tjp13730-fig-0008){ref-type="fig"}, [9](#tjp13730-fig-0009){ref-type="fig"}, [10](#tjp13730-fig-0010){ref-type="fig"}), randomly‐parameterized models resulting in spontaneous AP generation in the cell models (coloured lines) and randomly‐parameterized models resulting in non‐spontaneous or non‐AP generating model cells (grey lines) are all shown.](TJP-597-4533-g013){#tjp13730-fig-0012}

![Variation of action potential morphology in model iPSC‐CM populations\
*A*, APs of spontaneously beating cells (*n* = 25,434) generated by varying one current at a time (*I* ~Na~, *I* ~CaL~, *I* ~Kr~, *I* ~f~ and *I* ~K1~). *B*, APs of spontaneously beating cells (*n* = 17,139) generated by varying the same five currents simultaneously. *C*, representative AP time courses of spontaneously beating cells at various pacing frequencies. *D*--*F*, comparison of AP morphology in the populations of models (colour) and experimental iPSC‐CM data (black). Each coloured point represents a spontaneously beating cell created by varying a single current (*A*), or by varying all five currents simultaneously (*B*). *G*, mean ± SD of AP morphology measures for each population, normalized to the baseline model AP.](TJP-597-4533-g014){#tjp13730-fig-0013}

A final population was built using the same methodology but by varying the kinetics of the five specified currents simultaneously (shown as effects on the AP in blue in Fig. [13](#tjp13730-fig-0013){ref-type="fig"}). The outputs of the spontaneously beating AP models from the single‐current variation populations are shown in Fig. [13](#tjp13730-fig-0013){ref-type="fig"} *A* and the spontaneously beating AP generating models from the five‐current simultaneously varied population are shown in Fig. [13](#tjp13730-fig-0013){ref-type="fig"} *B*. Each cell in the resulting populations can be categorized into one of three groups: spontaneously beating cells, stimulated beating cells or cells excluded from analysis. 'Spontaneously beating cells' maintain automaticity with a viable AP and are most representative of the experimentally observed iPSC‐CMs. The baseline model would be categorized in the spontaneous beating subpopulation. 'Stimulated beating cells' are model cells that result in a viable AP with the application of a stimulus current but are non‐spontaneously beating (not shown). Cells were not analysed if they did not fully repolarize (MDP \> −40 mV, AP amplitude \<70 mV) or exhibited non‐control/non‐healthy AP morphology (e.g. alternans). Additionally, cells with non‐physiological calcium handling (determined as CaT amplitude greater than 3 SDs of the experimental average in Fig. [10](#tjp13730-fig-0010){ref-type="fig"} *B*) were excluded from the analysis.

For the cell population subject to single‐current variation, only the *I* ~K1~ variation population produced a stimulated beating subpopulation that required an external stimulus. A random selection of models from the spontaneously beating AP generating populations is shown in Fig. [13](#tjp13730-fig-0013){ref-type="fig"} *C* to illustrate the range of beating rates and AP morphologies observed. All subsequent analyses were conducted in the subpopulation generating spontaneously beating APs. Variation in AP morphology markers within each population of models is shown in Fig. [13](#tjp13730-fig-0013){ref-type="fig"} *D--G*. Individual coloured points in Fig. [13](#tjp13730-fig-0013){ref-type="fig"} *D--F* represent a single model in the given population. Additionally, these outputs are compared w2ith experimentally measured iPSC‐CM outputs shown as black dots and lines (Ma *et al*. [2011](#tjp13730-bib-0051){ref-type="ref"}; Doss *et al*. [2012](#tjp13730-bib-0016){ref-type="ref"}; Cordeiro *et al*. [2013](#tjp13730-bib-0011){ref-type="ref"}; Ma *et al*. [2015](#tjp13730-bib-0050){ref-type="ref"}; Es‐Salah‐Lamoureux *et al*. [2016](#tjp13730-bib-0018){ref-type="ref"}; Herron *et al*. [2016](#tjp13730-bib-0026){ref-type="ref"}), as was performed for the baseline model in Fig. [11](#tjp13730-fig-0011){ref-type="fig"}. It should be noted that the plots show the SE for the experimental data, meaning that the full range of experimental behaviour is larger than represented by the black points. The range of individual models in the single‐current variation populations can serve as a form of sensitivity analysis: for a given morphology marker, the widest spread of models is indicative of increased sensitivity to the varied current. For example, the maximal upstroke velocity is sensitive to *I* ~Na~ and thus the models from the *I* ~Na~ varied population show the largest range of upstroke velocity values (Fig. [13](#tjp13730-fig-0013){ref-type="fig"} *F*, distribution of green points along the *y*‐axis). Finally, the population with simultaneous variation of five ionic currents shows the largest range of variability in all AP morphology markers and is the population most representative of the full experimentally observed space. This serves as a first step in modelling known variability of iPSC‐CMs at the ionic level, resulting in the recapitulation of observed variability in iPSC‐CMs at the whole‐cell level.

Model prediction: ionic current block {#tjp13730-sec-0320}
-------------------------------------

To further validate the model population, we predicted the effect of ionic current blockers on the model population. We simulated the effect of drugs that have been experimentally studied in iPSC‐CMs: TTX (*I* ~Na~ block), E‐4031 (*I* ~Kr~ block) and nifedipine (*I* ~CaL~ block). For each drug, we simulated a concentration that had been studied across several experimental datasets. We modelled drug effects as a simple pore block. IC~50~ values for each cell in the population were randomly selected within the range of experimentally observed IC~50~ values in stem cell‐derived cardiomyocytes (Peng *et al*. [2010](#tjp13730-bib-0073){ref-type="ref"}; Ma *et al*. [2011](#tjp13730-bib-0051){ref-type="ref"}; Harris *et al*. [2013](#tjp13730-bib-0025){ref-type="ref"}; Gibson *et al*. [2014](#tjp13730-bib-0021){ref-type="ref"}; Moreau *et al*. [2017](#tjp13730-bib-0055){ref-type="ref"}). The ranges of IC~50~ values, and corresponding percentage ionic current block, are described in Table [4](#tjp13730-tbl-0004){ref-type="table"}. For example, when modelling 10 µ[m]{.smallcaps} TTX, each model cell had a randomly determined IC~50~ within the experimental range, resulting in 88%--94% *I* ~Na~ block. Beginning at the previously determined control steady‐state initial conditions, each simulation was run for 200 s with drug applied, and the final AP was analysed. All simulated results shown are in spontaneously beating model cells. The percentage change in the AP parameter associated with the blocked current is described in Table [4](#tjp13730-tbl-0004){ref-type="table"}, and sample APs for each drug are shown in Fig. [14](#tjp13730-fig-0014){ref-type="fig"}. Only the subpopulations of models that resulted in spontaneous beating and normal repolarization after drug application were analysed. Additionally, the TTX response was only analysed in the subpopulation of model cells with more than −10 pA pF^−1^ peak *I* ~Na~ during the control (non‐drug) AP. The size and results of the analysed model subpopulations are reported in Table [4](#tjp13730-tbl-0004){ref-type="table"}. It should be noted that the baseline model has a peak *I* ~Na~ of −29.2 pA pF^−1^ during the AP. Models without substantial *I* ~Na~ during the AP are unaffected by TTX and were omitted for clarity. A highly variable iPSC‐CM response to TTX and other sodium channel blockers has also been observed experimentally (Sheng *et al*. [2012](#tjp13730-bib-0084){ref-type="ref"}).

###### 

Simulation specifics and model population outputs for response to ionic current blockers

                                                                    TTX                   Nifedipine              E‐4031
  ----------------------------------------------------- --------------------------- ---------------------- ---------------------
  Concentration                                             10 µ[m]{.smallcaps}      30 n[m]{.smallcaps}    10 n[m]{.smallcaps}
  Ionic current blocked                                          *I* ~Na~                 *I* ~CaL~              *I* ~Kr~
  Range of IC~50~ values (n[m]{.smallcaps})                   640--13 55^1,2^           30--39^1,3,4^          7--17^3,4,5^
  \% Current block                                                88--94%                  72--77%                47--59%
  Output measured                                        Maximum upstroke velocity         APD~90~                APD~90~
  Experimental output w/drug (range of dataset means)        16.7--60%^1,6,7^        67.7--88.9%^1,3,4,8^   113--160%^1,3,4,8^
  Output w/drug in model subpopulation                         48.6 ± 27.5%              89.8 ± 5.1%           121.8 ± 10.4%
  Model subpopulation (*n*)                                        1057                     11 894                 8398

1, Ma *et al*. [2011](#tjp13730-bib-0051){ref-type="ref"}; 2, Moreau *et al*. [2017](#tjp13730-bib-0055){ref-type="ref"}; 3, Peng *et al*. [2010](#tjp13730-bib-0073){ref-type="ref"}; 4, Gibson *et al*. [2014](#tjp13730-bib-0021){ref-type="ref"}; 5, Harris *et al*. [2013](#tjp13730-bib-0025){ref-type="ref"}; 6, Scheel *et al*. [2014](#tjp13730-bib-0079){ref-type="ref"}; 7, Jonsson *et al*. [2012](#tjp13730-bib-0033){ref-type="ref"}; 8, Hortigon‐Vinagre *et al*. [2016](#tjp13730-bib-0028){ref-type="ref"}.
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![Sample APs showing the effect of ion channel blockers within the model population\
Showing the same cellular models in the control (solid lines) and drugged (dashed lines) conditions. Three cells are shown for each drug, representing a cell with a change in the given AP parameter near the population mean (cell 2) (± 1 SD). The mean ± SD for the full population are described in Table [4](#tjp13730-tbl-0004){ref-type="table"}. Drug effects are shown for (*A*) TTX, (*B*) nifedipine and (*C*) E‐4031.](TJP-597-4533-g015){#tjp13730-fig-0014}

The drug‐induced changes to AP morphology predicted by our model population falls within the experimentally observed range, as characterized in Table [4](#tjp13730-tbl-0004){ref-type="table"} (Peng *et al*. [2010](#tjp13730-bib-0073){ref-type="ref"}; Ma *et al*. [2011](#tjp13730-bib-0051){ref-type="ref"}; Jonsson *et al*. [2012](#tjp13730-bib-0033){ref-type="ref"}; Gibson *et al*. [2014](#tjp13730-bib-0021){ref-type="ref"}; Scheel *et al*. [2014](#tjp13730-bib-0079){ref-type="ref"}; Hortigon‐Vinagre *et al*. [2016](#tjp13730-bib-0028){ref-type="ref"}). It should be noted that there is a large range of experimentally observed variation in the effects of each of these drugs. Experimental data shown in Table [4](#tjp13730-tbl-0004){ref-type="table"} include data from paced and spontaneously beating cells, which may contribute to this variability. However, for TTX, Jonsson *et al*. ([2012](#tjp13730-bib-0033){ref-type="ref"}) shows a similar range of change in upstroke velocity in paced and spontaneously beating cells treated with TTX. Additionally, Hortigon‐Vinagre *et al*. ([2016](#tjp13730-bib-0028){ref-type="ref"}) show that cell line differences have an impact on the observed response to nifedpine and E‐4031 in spontaneously beating APs. Hortigon‐Vinagre *et al*. ([2016](#tjp13730-bib-0028){ref-type="ref"}) and Jonsson *et al*. ([2012](#tjp13730-bib-0033){ref-type="ref"}) reported AP outputs in spontaneously beating cells, whereas the other studies reported AP outputs at 1 Hz pacing. Qualitatively, experimental results across these experimental protocols show a similar response to each ionic channel blocking drug. Our comparison of model outputs with the experimental range reported in Table [4](#tjp13730-tbl-0004){ref-type="table"} serves to show that our model population can replicate this qualitative response to simple pore block.

Table [4](#tjp13730-tbl-0004){ref-type="table"} shows the range of the mean behaviour amongst the datasets cited, although the full range of behaviour in individual cells between these datasets is even larger. As discussed previously when characterizing the baseline AP morphology, it is impossible to pinpoint 'normal' iPSC‐CM response. There is a wide range of variability in the ionic currents regulating iPSC‐CM APs, and this is reflected in the range of responses to a particular drug.

Immature and mature phenotypes {#tjp13730-sec-0330}
------------------------------

We next compared representative immature and mature model phenotypes. The previously described baseline model was used as the representative immature model. The representative mature model was created using the baseline model with a 100% increase in maximal conductance of *I* ~K1~ and a 45% increase in maximal conductance of *I* ~Na~. These changes represent the relative increase in *I* ~K1~ and *I* ~Na~ from the immature to mature phenotype, as characterized experimentally by the Jalife Lab (Figs [3](#tjp13730-fig-0003){ref-type="fig"} *B* and [9](#tjp13730-fig-0009){ref-type="fig"}). These increases in *I* ~K1~ and *I* ~Na~ are proportional to the increase in *I* ~K1~ and *I* ~Na~ peak current between iPSC‐CMs cultured on glass (immature) and PDMS (mature) reported in Herron *et al*. ([2016](#tjp13730-bib-0026){ref-type="ref"}). The behaviour of the immature and mature models is compared in Fig. [15](#tjp13730-fig-0015){ref-type="fig"}. The APs of the immature and mature models are shown in Fig. [15](#tjp13730-fig-0015){ref-type="fig"} *A*, and the AP morphology markers for each model are compared with experimentally measured APs from the Jalife Lab in Fig. [15](#tjp13730-fig-0015){ref-type="fig"} *B*. Cell outputs (experimental and computational) were normalized to the average value of the experimental iPSC‐CMs cultured on PDMS (Fig. [15](#tjp13730-fig-0015){ref-type="fig"} *B*, black). Finally a multivariable regression model, created using the same methodology as described for the baseline model (Sobie, [2009](#tjp13730-bib-0085){ref-type="ref"}) and shown in Fig. [11](#tjp13730-fig-0011){ref-type="fig"} *E*, was used to conduct sensitivity analysis on both the mature and baseline/immature models, and a comparison of the results is shown in Fig. [15](#tjp13730-fig-0015){ref-type="fig"} *C*.

![Comparison of immature and mature cellular models\
*A*, AP for the immature (baseline) cellular model compared to AP for a representative mature cellular model. Immature and mature cellular models determined by scaling *g* ~K1~ and *g* ~Na~ based on peak currents reported in iPSC‐CMs with control (immature) and maturation‐promoting cell preparations (Herron *et al*. [2016](#tjp13730-bib-0026){ref-type="ref"}). *B*, comparison of models and experimental AP morphology for mature and immature cell‐types. Experimental data are from the Jalife Lab (Herron *et al*. [2016](#tjp13730-bib-0026){ref-type="ref"}). All of the model and experimental data were normalized to the Jalife Lab mature experimental dataset average. *C*, comparison of sensitivity analysis immature and mature models using multivariable regression. Only parameters with regression coefficients \>0.3 are shown.](TJP-597-4533-g016){#tjp13730-fig-0015}

For all four AP morphology markers (MDP, AP amplitude, APD~90~ and maximal upstroke velocity), the mature model (Fig. [15](#tjp13730-fig-0015){ref-type="fig"} *B*, red dots) is within the experimental range for mature cells (shown as black points in Fig. [15](#tjp13730-fig-0015){ref-type="fig"} *B*). The experimental AP data, which was not utilized in fitting the mature model, serves to validate that the mature model is representative of the experimentally matured iPSC‐CMs. The resulting mature model diastolic membrane potential (MDP~Mature,\ Model~ = −77.4 mV) is representative of the average experimentally matured cells (MDP~Mature,\ Ex~ *~p~* = −77.5 mV) and has a more hyperpolarized diastolic membrane potential than the immature model (MDP~Immature,\ Model~ = −75.6 mV). The AP amplitude of the mature model population is larger than the immature model population (Amp~Mature,Model~ = 108 ± 6 mV, Amp~Immature,Model~ = 90 ± 9 mV), which is consistent with the experimentally observed trend of a larger AP amplitude in mature cells (Amp~Mature,Ex~ *~p~* = 117 ± 6 mV, Amp~Immature,Ex~ *~p~* = 105 ± 16 mV). Similarly, the APD in the mature population is slightly longer than the immature population (APD~90,Mature,Model~ = 347 ± 77 ms, APD~90,Immature,Model~ = 340 ± 74 ms), which is consistent with the experimental results (APD~90,Mature,Ex~ *~p~* = 453 ± 113 ms, APD~90,Immature,Ex~ *~p~* = 437 ± 173 ms). Finally, for maximal upstroke velocity (dV/dt), the mature model value (dV/dt~Mature,Model~ = 199 mV ms^−1^) is within the experimentally measured range (dV/dt~Mature,Ex~ *~p~* = 147 ± 87 mV ms^−1^) and has a much higher upstroke velocity than the immature model value (dV/dt~Immature,Model~ = 33 mV ms^−1^), as would be expected in a more mature cell.

Maturation: population‐based insights {#tjp13730-sec-0340}
-------------------------------------

Notably, experimentally recorded mature iPSC‐CMs retained spontaneous beating, although our mature model cells required stimulation to beat. This indicates that there was either an excess of *I* ~K1~ in our representative mature model, or that other currents compensate for the increased *I* ~K1~, allowing the mature experimental cells to retain spontaneous beating at more negative maximum diastolic potentials. This led us to analyse our population of spontaneous beating cells and explore a computational subpopulation of cells that exhibited a mature phenotype, at the same time as retaining spontaneous beating. One of the advantages of a population‐based modelling approach is the ability to utilize a component dissection approach to identify plausible ionic mechanisms of known phenotypes. As a test case, we examined the immature and mature phenotypes in our model iPSC‐CM population. We formed two subpopulations of cells from the five‐current variation population (Fig. [13](#tjp13730-fig-0013){ref-type="fig"} *B*), based on phenotype. Based on the experimental data from the Jalife Lab, we determined ranges of cellular MDP and maximal upstroke velocity outputs that defined our immature and mature model subpopulations. The cut‐off regions for MDP and upstroke velocity were determined based on the experimental outputs for matured cells (black points, Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *A*) compared to control cells, which exhibit a more immature phenotype (Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *A*, open circles). We categorized mature cells as those with hyperpolarized diastolic potentials and high upstroke velocity (MDP \<−75 mV, dv/dt~max~ \>85 mV ms^−1^) ( Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *A*, red) and immature cells as those with depolarized diastolic potentials and low upstroke velocity (MDP \>−75 mV, dv/dt~max~ \<85 mV ms^−1^) (Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *A*, blue). A third group of cellular models that did not meet either the immature or mature phenotype criteria (Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *A*, grey) were not analysed.

![Comparison of mature and immature iPSC‐CM model subpopulations\
*A*, division of model population into mature and immature phenotypes (using five‐current variation population with simultaneous variation in *I* ~Na~, *I* ~CaL~, *I* ~Kr~, *I* ~F~ and *I* ~K1~ parameters). Experimental data are from the Jalife Lab (Herron *et al*. [2016](#tjp13730-bib-0026){ref-type="ref"}). Model subpopulation shown in red (*n* = 325) represents mature phenotypes with MDP \<−75 mV and maximal upstroke velocity \>85 V s^−1^. The model subpopulation shown in blue (*n* = 13 759) represents immature phenotypes with MDP \>−75 mV and maximal upstroke velocity \<85 V s^−1^. The model subpopulation shown in grey was not analysed in this comparison. *B*, the four model parameters with the largest difference between the mature and immature model subpopulations. For each subpopulation, parameter averages and SDs are shown as the percentage change from the baseline model parameter value. *C*, steady‐state inactivation for *I* ~Na~ in the mature and immature model subpopulations. Individual cells (light colours) and subpopulation average parameter values (darker colored lines) are shown. *D*, peak *I* ~K1~ and *I* ~Na~ for the *I*--*V* relationship of each cell in the model subpopulations were compared with data reported in Herron *et al*. ([2016](#tjp13730-bib-0026){ref-type="ref"}). Model and experimental values are shown as the percentage change from the immature to mature phenotype.](TJP-597-4533-g017){#tjp13730-fig-0016}

To compare mature and immature populations, we looked at the underlying model parameters that had the largest difference between the two populations. To normalize parameter values, the population analysis was conducted using percentage change in parameter value from the baseline model parameter value, shown in Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *B*. The three currents identified in this analysis were *I* ~K1~, *I* ~Na~ and *I* ~f~. Maximal conductance parameters for all three currents were identified, with lower maximal conductance of *I* ~K1~ and *I* ~Na~ found in the immature cells, which is consistent with the findings in Herron *et al*. ([2016](#tjp13730-bib-0026){ref-type="ref"}). Both currents are directly related to the defining characteristics of mature and immature subpopulations because increased *I* ~K1 ~hyperpolarized the MDP and increased *I* ~Na~ increased the maximal upstroke velocity. In addition to *g* ~K1~ and *g* ~Na~, the immature population also exhibited increased *g* ~f~, which is consistent with an immature cardiomyocyte phenotype (Karakikes *et al*. [2015](#tjp13730-bib-0036){ref-type="ref"}; Kim *et al*. [2015](#tjp13730-bib-0038){ref-type="ref"}).

In additional to maximal conductances, *x* ~6~ in the formulation of the *I* ~Na~ inactivation gate was also identified. The decrease in the *x* ~6~ parameter impacts the shift in the *I* ~Na~ inactivation (*h* and *j*) steady‐state curves, as described in the Methods; see eqns [(8)](#tjp13730-disp-0008){ref-type="disp-formula"}--[(9)](#tjp13730-disp-0009){ref-type="disp-formula"}. A decrease in *x* ~6~ in the mature models corresponds to increased *I* ~Na~ in the physiological voltage range by shifting the steady‐state inactivation curve toward the physiological range, as shown for the model populations in Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *C* (individual models in light colours, population averages in dark colours). Similarly, *x* ~6~ shifts the negatively sloped portion of the time constant of decay curve, causing an increased time constant of inactivation in the relevant range for the upstroke of the AP (−70 to −50 mV). An increase in time constant slows the inactivation of *I* ~Na~. Collectively, this change in *x* ~6~ results in more *I* ~Na~ during the upstroke of the AP, demonstrating a combined impact with the increase in *g* ~Na~ in mature cells, which all contribute to the increased maximal upstroke velocity. Additionally, Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *C* shows that there are immature cells (Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *C*, blue) with steady‐state inactivation curves resulting in *V* ~half~ in the mature range (−85 to −50 mV) but no mature cells (Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *C*, pink) with *V* ~half~  \<--85 mV. This suggests that, to reach a maximal upstroke velocity \>85 mV ms^−1^, our cut‐off for mature cells, the cellular *I* ~Na~ model needs to fall within a smaller range of steady‐state inactivation behaviours. This positive shift in the inactivation curve, and a corresponding increase in *g* ~Na~ (Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *B*), allows for a large influx of *I* ~Na~ during the AP upstroke, resulting in a more mature phenotype with a high upstroke velocity. Immature cells with low maximal upstroke velocity have a much wider range of steady‐state inactivation curves that are compensated by a wide range of maximal *I* ~Na~ conductance values to keep the upstroke velocity within the immature range. It should be noted that the baseline model can maintain spontaneous beating with complete *I* ~Na~ block, as has been shown experimentally in iPSC‐CMs (Guo *et al*. [2011](#tjp13730-bib-0024){ref-type="ref"}; Sheng *et al*. [2012](#tjp13730-bib-0084){ref-type="ref"}). Thus, some cells in immature population may have *I* ~Na~ parameterizations that result in a miniscule *I* ~Na~ during spontaneous beating.

The population‐based approach identified three currents (*I* ~Na~, *I* ~K1~ and *I* ~f~) that are appreciably different between the immature and mature subpopulations (Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *B*). Two of these currents have been experimentally validated by the Jalife Lab, as shown in Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *D*. Experimental measurements in matured iPSC‐CMs show enhanced *I* ~Na~ and *I* ~K1~ compared to the control cells. The experimental and *in silico* results are shown in Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *D* for the mature cells. The mature cellular outputs were normalized to the respective average experimental or *in silico* immature outputs. In the model subpopulations, the peak current from the *I*--*V* curve for each cell in the mature population was normalized to the mean value of the peak current in the immature population. For *I* ~K1~, we analysed the outward portion *I* ~K1~, which occurs in the physiological voltage range (*V* ~m~ \>85 mV) for iPSC‐CMs.

Although the MDP and upstroke velocity are known to be directly linked to the maximal conductance of *I* ~K1~ and *I* ~Na~, respectively, this methodology also identified *g* ~f~ and the kinetics of *I* ~Na~ that contribute to the mature phenotype. In the future, this approach can also be expanded to identify mechanisms of disease states. The data used to construct this model were from presumed healthy iPSC‐CMs, although a similar approach could be used to identify molecular mechanisms of increased proclivity to arrhythmia or susceptibility to proarrhythmic drugs in a diseased population model.

Discussion {#tjp13730-sec-0350}
==========

In the present study, we present a modelling approach for *in silico* representation of iPSC‐CMs. We used a 'bottom‐up' approach by developing models of subcellular components, namely individual ionic currents and Ca^2+^ handling proteins. The study was conducted in collaboration with a number of experimental laboratories who generously provided data recorded from iPSC‐CMs in their respective laboratories. These data allowed us to consider measured variability in ionic currents and their underlying processes. To minimize the number of model parameters, as well as to prevent overfitting, we utilized a simple formulation of the ionic currents with fewer parameters than other commonly used cardiomyocyte or ionic current models (ten Tusscher *et al*. [2004](#tjp13730-bib-0088){ref-type="ref"}; Moreno *et al*. [2011](#tjp13730-bib-0057){ref-type="ref"}; O\'Hara *et al*. [2011](#tjp13730-bib-0065){ref-type="ref"}).

To gain a complete representation of the behaviour of iPSC‐CMs, a single average behaviour is insufficient. There is no experimental consensus on which iPSC‐CM recording might represent average or representative behaviour. We aimed to determine whether variability at the subcellular level was sufficient to replicate this wide range of whole‐cell iPSC‐CM phenotypes. Figure [13](#tjp13730-fig-0013){ref-type="fig"} *D--F* shows that our *in silico* population, informed purely by the distribution of experimentally observed kinetic behaviour, reproduces the range of whole‐cell behaviours observed experimentally. Within this population, each individual model, including the baseline model, is presumed to be an equally valid representation of an iPSC‐CM.

In developing a collection of *in silico* iPSC‐CMs that reflect phenotypic cellular variability, we explored populations with single current variation, as well as simultaneous variation in five key currents. Although the five‐current variation population provides the most complete coverage of the experimentally observed parameter space, comparing the different populations developed can provide additional insight (Fig. [13](#tjp13730-fig-0013){ref-type="fig"}). For each of the single‐current variation populations, there is a relatively narrow range of variability in whole‐cell AP morphology. Additionally, almost all of the models created through single current variation resulted in a viable and spontaneously beating cellular model. However, when variation in multiple currents was included in the cell representation, there was a much larger range of AP morphologies including 'non‐viable' *in silico* iPSC‐CMs that were not possible to excite or did not repolarize.

The results described above are not surprising and may stem from physiologically relevant regulatory phenomena that require correlation and co‐ordination of ionic currents within individual cells. For example, to have sufficient net repolarizing current during the AP, there must be a mechanism of coregulation for repolarizing currents (Xiao *et al*. [2008](#tjp13730-bib-0097){ref-type="ref"}; Varro & Baczko, [2011](#tjp13730-bib-0093){ref-type="ref"}). In iPSC‐CMs, and other fetal‐like cell types, there is a particularly low density of *I* ~K1~ compared to adult cardiomyocytes (Bett *et al*. [2013](#tjp13730-bib-0006){ref-type="ref"}; Meijer van Putten *et al*. [2015](#tjp13730-bib-0053){ref-type="ref"}; Vaidyanathan *et al*. [2016](#tjp13730-bib-0092){ref-type="ref"}). Although our cellular populations include a large range of variation in *I* ~K1~, there is much lower *I* ~K1~ density throughout these populations than there would be in an adult ventricular cardiomyocyte (Karakikes *et al*. [2015](#tjp13730-bib-0036){ref-type="ref"}). In particular, the lack of *I* ~K1~ plays a key role in the spontaneously beating phenotype, which is characteristic of these cells (Kim *et al*. [2015](#tjp13730-bib-0038){ref-type="ref"}). Thus, there is a balance of repolarizing currents in iPSC‐CMs that allow for spontaneous beating, at the same time as maintaining the cells ability to fully repolarize. Because every cell in our a populations maintains spontaneous beating (Fig. [13](#tjp13730-fig-0013){ref-type="fig"}), every cell also requires the coregulation of ionic current density that maintains a unique balance of repolarizing currents to accommodate the relatively low *I* ~K1~.

Coregulation has been shown experimentally in numerous studies of cardiac cells (Deschenes *et al*. [2008](#tjp13730-bib-0014){ref-type="ref"}; Xiao *et al*. [2008](#tjp13730-bib-0097){ref-type="ref"}; Milstein *et al*. [2012](#tjp13730-bib-0054){ref-type="ref"}). For example, Liu *et al*. ([2016](#tjp13730-bib-0048){ref-type="ref"}) showed that there is cotranslation of protein subunits, leading to functional regulation of cellular ionic currents within a single cell. Cotranslation may also serve as a mechanism to maintain the balance of ionic currents within a single cell. Banyasz *et al*. ([2011](#tjp13730-bib-0001){ref-type="ref"}) showed that there is a mechanism by which individual cells regulate net ionic current, despite a wide range of variability in density of individual currents. Specifically, there was a linear relationship between the inward and outward currents measured via AP dissection, indicating a mechanism of cellular co‐ordination between key inward and outward currents. The results of our population‐based studies suggest a similar co‐ordination in the ionic currents of iPSC‐CMs, allowing for a wide range of variation in subcellular mechanisms at the same time as maintaining functional AP dynamics. Intriguingly, a recent combined computational and experimental study revealed that variable inward calcium and outward potassium currents in mouse ventricular myocytes compensate for each other to generate normal calcium transients and contractile responses (Rees *et al*. [2018](#tjp13730-bib-0074){ref-type="ref"}). This suggests that a feedback mechanism sensing global cytosolic calcium levels might be sufficient to regulate ionic conductances. Clinically, genetic modifiers have been seen to modify the severity of long QT syndrome type 2. Patients with the same hERG mutations have differential severity in QT prolongation, depending on the presence of other mutations that coregulate cellular repolarization (Chai *et al*. [2018](#tjp13730-bib-0010){ref-type="ref"}). The present study provides a framework that can be expanded to elucidate these types of feedback and coregulation mechanisms in iPSC‐CMs, which directly relate to mechanisms of adult human cardiomyocyte behaviour.

Sources of cellular variation are often unclear, although experimental manipulation allows us to directly compare known sources of variation. Using data from experimentally manipulated cells, we were able to validate our framework for determining sources of variation leading to known phenotypes. The use of data from maturation promoted iPSC‐CMs allowed us to conduct a two‐pronged analysis of cell maturation. Beginning with a bottom‐up approach, we showed that a single cell model can accurately predict a more mature phenotype based on known sources of variation, as shown in Fig. [15](#tjp13730-fig-0015){ref-type="fig"}. Additionally, we used a top‐down approach to test whether the parameter space used to randomly generate our model populations covered the subcellular range of maturation behaviour. As hypothesized, the whole‐cell behaviour within the population predicts a range of maturation, as shown in Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *A*. Additionally, our population‐based approach identified the same changes in key currents (*I* ~Na~ and *I* ~K1~) (Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *D*) when stratifying subpopulations of mature and immature cellular models.

This same top‐down approach can be used to compare other subpopulations. We also used this approach to compare atrial and ventricular‐like subpopulations. To define atrial and ventricular‐like subpopulations, we used a metric used experimentally to classify iPSC‐CMs: APD~r~ = (APD~40~ − APD~30~)/(APD~80~ -- APD~70~) (Ma *et al*. [2011](#tjp13730-bib-0051){ref-type="ref"}). Ventricular‐like cells are defined as APD~r~ \> 1.5, and atrial‐like cells are defined as APD~r~ \< 1.5. Using the atrial and ventricular‐like subpopulations, we conducted the same analysis shown in Fig. [16](#tjp13730-fig-0016){ref-type="fig"} *B*. Our analysis on the atrial and ventricular‐like populations identified the maximal conductance parameters for *I* ~Kr~ and *I* ~CaL~ as having the largest differences between the two subpopulations. This is consistent with experimental works by Lieu *et al*. ([2013](#tjp13730-bib-0047){ref-type="ref"}) in embryonic stem cell‐derived cardiomyocytes (ESC‐CMs), which identified the increased *I* ~Kr~ and *I* ~CaL~ in ventricular‐like compared to atrial‐like ESC‐CMs. They additionally showed decreased *I* ~f~ in atrial‐like ESC‐CMs, which our analysis did not identify. The APD~r~ criterion was used to define the atrial and ventricular‐like subpopulations to be consistent with the experimental methodology, and to show that our model captures these experimental results. However, there is debate over the precision of this definition of atrial *vs*. ventricular cells (Du *et al*. [2015](#tjp13730-bib-0017){ref-type="ref"}; Giles & Noble, [2016](#tjp13730-bib-0022){ref-type="ref"}). This criterion considers only the AP morphology with repsect to determining the chamber specificity of the cells, which ignores many other key physiological differences between the two cell types.

The large range of experimentally observed variability in iPSC‐CMs, which is recapitulated within the populations of models described in the present study, allows us to examine the mechanistic origin of phenotypic differences (Sarkar & Sobie, [2011](#tjp13730-bib-0078){ref-type="ref"}; Yang *et al*. [2015](#tjp13730-bib-0100){ref-type="ref"}; Morotti & Grandi, [2017](#tjp13730-bib-0059){ref-type="ref"}; Passini *et al*. [2017](#tjp13730-bib-0072){ref-type="ref"}). Properly utilized, the phenotypic variation in iPSC‐CMs can be a strength of this experimental approach, allowing us to better understand the mechanistic underpinnings of phenotypic diversity, which is of course also observed in patients. iPSC‐CMs in conjunction with computational approaches provide a unique opportunity to conduct high throughput component dissection of phenotypes of interest, which ultimately can be linked to patient‐specific phenotypes.

The present study can also serve as a basis to 'translate' the patient‐specific iPSC‐CM behaviours from the immature fetal‐like phenotype to a predictive model of adult cardiomyocyte behaviour. As has been noted experimentally, our model population reflects the differences in AP morphology between iPSC‐CMs and adult ventricular cells. On average, our model population has a more positive resting membrane potential, slower AP upstroke velocity, slower CaT time to peak and reduced CaT amplitude compared to adult ventricular cell models (ten Tusscher *et al*. [2004](#tjp13730-bib-0088){ref-type="ref"}; O\'Hara *et al*. [2011](#tjp13730-bib-0065){ref-type="ref"}). Understanding the mechanisms of these differences is the first step to translating between iPSC‐CM and the adult cardiac response. Critical differences between ionic currents in adult and iPSC‐CM have been noted in computational and experimental studies (Karakikes *et al*. [2015](#tjp13730-bib-0036){ref-type="ref"}; Paci *et al*. [2015](#tjp13730-bib-0069){ref-type="ref"}). Translation between iPSC‐CM and adult phenotypes will be critical with respect to the use of iPSC‐CMs for drug safety and discovery in the human population. Gong & Sobie ([2018](#tjp13730-bib-0023){ref-type="ref"}) have developed a cross‐cell type regression model that translates response to ionic current perturbations in an iPSC‐CM model to the predicted the response in an adult ventricular cardiomyocyte model. Additionally, Tveito *et al*. ([2018](#tjp13730-bib-0091){ref-type="ref"}) have developed a method of utilizing optically obtained experimental whole‐cell drug‐response data from immature iPSC‐CMs to computationally predict the effect in a mature iPSC‐CM phenotype, which serves as a more representative model of adult cardiomyocytes. In the future, these computational translation approaches can be coupled with our utilization of experimental data from multiple sources to further reconcile the phenotypic variability observed across iPSC‐CM datasets with patient‐specific adult cardiac phenotypes.

Limitations {#tjp13730-sec-0360}
===========

In part, the goal of this modelling approach was to fully parameterize a model from experimental data with the fewest parameters possible and still recapitulate complex behaviour that has been characterized in iPSC‐CMs. However, it should be noted that there is no complete experimental characterization of calcium handling, sodium handling or E‐C coupling in iPSC‐CMs. This a critical point of concern with respect to the adaptation of iPSC‐CMs in the study of drug and disease mechanisms. Furthermore, pumps and exchangers also lack experimental characterization in iPSC‐CMs. We have modelled the iPSC‐CM calcium handling based on all of the available experimental data, resulting in a more experimentally‐based iPSC‐CM calcium handling than prior modelling efforts. Our model captures the physiological reality for SR‐calcium release dependent on cytosolic concentration, faithfully reproduces the experimentally measured contribution of various calcium removal processes, and utilizes experimentally‐based calcium buffering parameters. Moreover, we are confident in the validity of adopting earlier model formulations of pumps and exchangers because these mechanisms maintain intrinsic transport stoichiometry and kinetics across various cells. Nonetheless, the implementation of phenomena that are not fully experimentally characterized in iPSC‐CMs remains a limitation of our model.

Additionally, an essential gap in knowledge remains related to the source of observed experimental variation. Because some of this variation may come from the cell‐culture process or the cell‐type, in future work, it would be beneficial to collect a full kinetic characterization of individual cells. A necessary next step is to fully parameterize a cellular model based on the kinetics of individual cells. This future goal will be required utilization of iPSC‐CMs for the pursuit of patient‐specific models.

Conclusions {#tjp13730-sec-0370}
===========

We have utilized multiple iPSC‐CM ion channel data sources to construct a range of ion channel models for key iPSC‐CM currents. We then utilized random selection of parameters from within the model ranges to inform development of a population of cellular level iPSC‐CM models. Several conclusions can be drawn: (i) variation in the underlying model parameters within the experimentally measured ranges were sufficient to encapsulate the complete diverse range of whole‐cell iPSC‐CM phenotypes that are observed experimentally; (ii) this method of deriving a population of model cells obviated the need for 'calibration' or selecting models that exhibit physiologically relevant electrical behaviour, beyond excluding non‐excitable or non‐repolarizing cells; and (iii) mature and immature iPSC‐CM phenotypes naturally emerge as subsets of the population.

The construction described in the presented study has many potential future applications that can aid our understanding of cardiac disease and drug testing. In conjunction with the existing CiPA protocol (Cavero & Holzgrefe, [2014](#tjp13730-bib-0009){ref-type="ref"}), the iPSC‐CM computational model in the present study can be applied to provide a better understanding of the parameter combinations that lead to proarrhythmic behaviours. This *in silico* population‐based framework for analysing the iPSC‐CM phenotype has the added advantage of being a high throughput analysis tool. Additionally, the models that we present can be readily expanded to include genetic mutations, pharmacological interventions, sex‐based differences and a variety of perturbations. Future studies could utilize coupled sheets of *in silico* tissue to test higher dimension arrhythmia proclivity and sustainability.
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###### Translational perspective

Induced pluripotent stem cell‐derived cardiomyocytes (iPSC‐CMs) have been developed as a promising *in vitro* method for addressing patient‐specific proclivity to cardiac disease and drug response. A well‐known limitation of iPSC‐CMs is the cell‐to‐cell variability observed in electrical activity. We hypothesize that, when captured in a computational framework, cell‐to‐cell variability may constitute a useful systems property that can allow the identification of a variety of phenotypic mechanisms and underlying causal components. We have developed a whole‐cell model of iPSC‐CMs comprising simple model components built on experimental data from multiple laboratories. By including a wide range of input data into the model, we built a population of cellular models to predict robust inter‐subject variability in iPSC‐CMs. This approach allows for a link between molecular mechanisms and the emergent cellular‐level iPSC‐CM phenotypes to be revealed. The mechanisms underlying immature and mature subpopulations are predicted and are consistent with the experimental data. In the future, the models presented may prove to be essential for integrating experimental and clinical data from a variety of sources, scales and modalities, allowing high throughput prediction of the link between patient phenotype and patient specific electrophysiology. The tools presented here can be readily expanded and applied for *in silico* screening and the prediction of drug effects on varied genetic backgrounds to predict patient pharmacological responses and even to guide therapy for specific patient therapy.

**Divya Kernik** is currently a PhD candidate in Biomedical Engineering at the University of California, Davis. She obtained a BS in Biomedical Engineering from Johns Hopkins University. The focus of her PhD work has been the development of computational methods that help to understand human‐derived cardiac cells, as reported in the present study. In the future, she aims to continue to use computational modelling to address questions in cardiac physiology and pharmacology, with the underlying goal of incorporating human diversity throughout these efforts.
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